<?xml version="1.0" encoding="UTF-8"?>
<projectSnippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7005743\results\search\drugs\results.xml">
   <result pre="foetal bovine serum (FBS) (Greiner), 100 U ml−1 penicillin (PEN, Lonza), 100 U ml−1" exact="streptomycin" post="(STR, Lonza), 2 mM L-glutamine (L-glu, Lonza), 1.5 mg ml−1 sodium bicarbonate"/>
   <result pre="handling (swabbing and weighing) was performed under light anesthesia using" exact="ketamine" post="to minimize animal suffering. (i) Ferret transmission experiments: Donor"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7005766\results\search\drugs\results.xml">
   <result pre="since the original landmark trials – corticosteroids in combination with" exact="azathioprine" post="have remained the established therapy since the 1970s, in"/>
   <result pre="study. Data from 22 patients with &quot;difficult-to-treat�? AIH showed that" exact="rituximab" post="improved aminotransferase and albumin values for up to 2"/>
   <result pre="clinical disease flares during this period and a reduction of" exact="prednisolone" post="dose was possible in 62% of cases, though never"/>
   <result pre="treated with standard volume plasma exchangeJHEP Reports12019447450 22Ni ThanN.HodsonJ.Schmidt-MartinD.TaubertR.WawmanR.E.BotterM.Efficacy of" exact="rituximab" post="in difficult-to-manage Autoimmune Hepatitis: Results from the International Autoimmune"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7010294\results\search\drugs\results.xml">
   <result pre="mosquito personal protective technologies (PPT), such as topical DEET or" exact="permethrin" post="impregnated clothing, show high efficacy in laboratory studies, they"/>
   <result pre="together with the wearing of clothing impregnated with the insecticide" exact="permethrin" post="[20]. However, achieving high uptake and compliance with PPT"/>
   <result pre="Mathematical modelling, considering populations of school children in Thailand wearing" exact="permethrin" post="impregnated school uniforms, suggests that repellent clothing could have"/>
   <result pre="fabrics in the U.S. Although the safety data available for" exact="permethrin" post="use during pregnancy is not as extensive as that"/>
   <result pre="DEET, the World Health Organization (WHO) considers topical application of" exact="permethrin" post="for scabies treatment compatible with breastfeeding [43]. However, there"/>
   <result pre="fetal pathologies of Zika led the U.S. CDC to recommend" exact="permethrin" post="impregnated clothing as a personal protective measure for pregnant"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7014709\results\search\drugs\results.xml">
   <result pre="in the half maximal inhibitory concentration for zidovudine, tenofovir, or" exact="lamivudine" post="between the K65R and K65R/S68G mutations, as demonstrated by"/>
   <result pre="were 301635, 301770, 301844, and 302335. The treatment regimens were" exact="tenofovir" post="(TDF), lamivudine (3TC), and efavirenz. Genotypic testing for drug"/>
   <result pre="301770, 301844, and 302335. The treatment regimens were tenofovir (TDF)," exact="lamivudine" post="(3TC), and efavirenz. Genotypic testing for drug resistance and"/>
   <result pre="4.BrennerBTurnerDOliveiraMMoisiDDetorioMCarobeneMMarlinkRGSchapiroJRogerMWainbergMAA V106M mutation in HIV-1 clade C viruses exposed to" exact="efavirenz" post="confers cross-resistance to non-nucleoside reverse transcriptase inhibitorsAIDS2003171F1F510.1097/00002030-200301030-0000112478089 5.Martinez-CajasJLWainbergMAOliveiraMAsahchopELDoualla-BellFLisovskyIMoisiDMendelsonEGrossmanZBrennerBGThe role"/>
   <result pre="resistance profile in vivo detected in most patients failing abacavir," exact="didanosine" post="and stavudineAntivir Ther20038217318212741630 21.Doualla-BellFAvalosABrennerBGaolatheTMineMGaseitsiweSOliveiraMMoisiDNdwapiNMoffatHet al.High prevalence of the K65R"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7017508\results\search\drugs\results.xml">
   <result pre="deal of concerns regarding second-line treatment options for MRMP, including" exact="tetracycline" post="or fluoroquinolones [7]. Some previous studies have reported no"/>
   <result pre="refractory mycoplasma pneumoniae pneumonia in school-aged childrenSci Rep201663703710.1038/srep3703727833154 19.YouSYJwaHJYangEAKilHRLeeJHEffects of" exact="methylprednisolone" post="pulse therapy on refractory mycoplasma pneumoniae pneumonia in childrenAllergy,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7019041\results\search\drugs\results.xml">
   <result pre="For infections, mice were anesthetized by intraperitoneal (i.p.) injection of" exact="ketamine" post="(100 mg/kg)/xylazine (10 mg/kg) and then inoculated intranasally (i.n.)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7019320\results\search\drugs\results.xml">
   <result pre="were scaled accordingly. For BRET experiments, we used Opti-MEM without" exact="phenol" post="red (Thermo Fisher Scientific) to minimize background fluorescence from"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7020004\results\search\drugs\results.xml">
   <result pre="lacking IFN-λ signaling sustain greater female reproductive tract infection when" exact="progesterone" post="is administered. Exogenous IFN-λ treatment confers an antiviral effect"/>
   <result pre="IFN-λ treatment confers an antiviral effect when mice receive both" exact="estradiol" post="and progesterone, but not progesterone alone. Further studies will"/>
   <result pre="effect when mice receive both estradiol and progesterone, but not" exact="progesterone" post="alone. Further studies will be necessary to delineate the"/>
   <result pre="modulated by the sex hormones required to maintain pregnancy, namely" exact="progesterone" post="and estrogens. Insufficient progesterone production has been associated with"/>
   <result pre="hormones required to maintain pregnancy, namely progesterone and estrogens. Insufficient" exact="progesterone" post="production has been associated with infertility and recurrent miscarriages"/>
   <result pre="example, Littauer and colleagues demonstrated that influenza virus infection disrupts" exact="progesterone" post="production and upregulates inflammatory mediators such as cyclooxygenase-2 and"/>
   <result pre="same group reported that viral load was negatively associated with" exact="progesterone" post="concentration, and reduced progesterone expression was correlated with preterm"/>
   <result pre="viral load was negatively associated with progesterone concentration, and reduced" exact="progesterone" post="expression was correlated with preterm birth in influenza virus-infected"/>
   <result pre="preterm birth in influenza virus-infected pregnant mice [148]. Administration of" exact="progesterone" post="to female mice following influenza A (H1N1) virus infection"/>
   <result pre="associated with luteal phase defectJ. Obstet. Gynecol. Neonatal Nurs.19851421221610.1111/j.1552-6909.1985.tb02229.x3847480 144.BaloghA.DitroiF.LampeG.Serum" exact="progesterone" post="levels in early imminent abortionActa Physiol. Hung.1985652752794013766 145.TaiP.WangJ.JinH.SongX.YanJ.KangY.ZhaoL.AnX.DuX.ChenX.Induction of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7020194\results\search\drugs\results.xml">
   <result pre="al. (2001) showed that chronic administration of the anti-epileptic drugs," exact="carbamazepine" post="or valproate, significantly decreased CD151 transcript levels in rat"/>
   <result pre="in A431 skin epidermoid carcinoma cells. They further showed that" exact="gefitinib" post="upregulated CD151 protein levels in MDA-MB-231 breast and A549"/>
   <result pre="study reporting CD151 mRNA downregulation after treatment with anti-epileptic drugs," exact="valproate" post="and carbamazepine (Hua et al., 2001), there were no"/>
   <result pre="CD151 mRNA downregulation after treatment with anti-epileptic drugs, valproate and" exact="carbamazepine" post="(Hua et al., 2001), there were no experiments conducted"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7020694\results\search\drugs\results.xml">
   <result pre="important target for the development of antiviral drugs, such as" exact="oseltamivir" post="(Tamiflu®) and zanamivir, both of which target the enzymatic"/>
   <result pre="h post infection (Nakamura et al., 2013). Interestingly, co-administration of" exact="oseltamivir" post="and the antibody after lethal challenge significantly improved the"/>
   <result pre="2015). These studies also demonstrated improved protection when co-administered with" exact="oseltamivir" post="(Tharakaraman et al., 2015). When administered post infection, VIS401-treated"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7020867\results\search\drugs\results.xml">
   <result pre="4 days and a single dose of 400 mg of" exact="hydrocortisone" post="IV was administered. Treatments with immunoglobulin IV or colchicine"/>
   <result pre="the most recommended management.6 There is also evidence that IV" exact="hydrocortisone" post="may be helpful to accomplish full recovery in DENV"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7023813\results\search\drugs\results.xml">
   <result pre="produce recombinant HAs, which were then purified and mixed with" exact="polysorbate" post="80 to form protein-detergent nanoparticles of 2~7 HA trimers"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7029021\results\search\drugs\results.xml">
   <result pre="on hMPV alternating epidemics. We tried to use the immunosuppressant" exact="cyclophosphamide" post="to suppress the immunity of mice, but the use"/>
   <result pre="(Invitrogen, USA), 2 mM L-glutamine, 100 U/ml penicillin and 100 μg/ml" exact="streptomycin" post="in an incubator with 5% CO2 at 37 °C. Viral"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7031735\results\search\drugs\results.xml">
   <result pre="as it enhanced serum antibody responses in immunosuppressed chickens after" exact="cyclophosphamide" post="treatment at 100 mg/kg for 3 days [63]. 2.2"/>
   <result pre="production of cytokines, including IL-1β and TNF-α, neutrophil infiltration, and" exact="nitric oxide" post="production 48 h after infection in vivo. Furthermore, aqueous"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7033529\results\search\drugs\results.xml">
   <result pre="apoptosisReproduction131200610311116388014 48LiuC.H.ChenL.H.Promotion of recombinant macrophage colony stimulating factor production by" exact="dimethyl sulfoxide" post="addition in Chinese hamster ovary cellsJ. Biosci. Bioeng.1032007454917298900 49BalcarcelR.R.StephanopoulosG.Rapamycin"/>
   <result pre="cells through the control of culture conditionsBiotechnol. Prog.212005223015903237 64XingL.RemickD.G.Mechanisms of" exact="dimethyl sulfoxide" post="augmentation of IL-1 beta productionJ. Immunol.17420056195620215879116 65MahajanP.B.Modulation of transcription"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7036648\results\search\drugs\results.xml">
   <result pre="BrumbackB, RobinsJMMarginal structural models to estimate the causal effect of" exact="zidovudine" post="on the survival of HIV-positive men. Epidemiology. 2000;11(5):561–570.10955409 67.GaleaSAn"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7041325\results\search\drugs\results.xml">
   <result pre="America indicated the presence of several haplotypes also in the" exact="nicotinamide" post="adenine dinucleotide (NADH) and dehydrogenase subunit 4 mitochondrial DNA"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7044130\results\search\drugs\results.xml">
   <result pre="onto companion plates containing 500 μl of Krebs-HEPES buffer. Afterward," exact="dextran" post="conjugated with FITC (FITC-dextran 1 mg/ml) was added to"/>
   <result pre="various transcytosis inhibitors in different concentration, including 10 μM of" exact="nystatin" post="(Sigma), 10 μM of chlorpromazine hydrochloride (CPZ, Sigma), 20"/>
   <result pre="concentration, including 10 μM of nystatin (Sigma), 10 μM of" exact="chlorpromazine" post="hydrochloride (CPZ, Sigma), 20 μM of dimethyl amiloride (DMA,"/>
   <result pre="μM of chlorpromazine hydrochloride (CPZ, Sigma), 20 μM of dimethyl" exact="amiloride" post="(DMA, Sigma), and 10 μM of colchicine (Sigma). Drugs"/>
   <result pre="a series of pharmacological inhibitors including bafilomycin (BFA), MG132, and" exact="chloroquine" post="(CQ), which target either autophagic or proteasomal degradation pathways,"/>
   <result pre="cells, we pretreated barrier cells with pharmacological inhibitors including Nystatin," exact="chlorpromazine" post="(CPZ), and dimethyl amiloride (DMA), which specifically inhibit caveolae-dependent"/>
   <result pre="cells with pharmacological inhibitors including Nystatin, chlorpromazine (CPZ), and dimethyl" exact="amiloride" post="(DMA), which specifically inhibit caveolae-dependent endocytosis, clathrin-dependent endocytosis, and"/>
   <result pre="of both the placenta barrier and the BBB. Using fluorescence-tagged" exact="dextran" post="as an indicator, our results revealed that ZIKV infection"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7045083\results\search\drugs\results.xml">
   <result pre="Immunol9122003105114 27DiamondL.DockhornR.J.GrossmanJ.KisickiJ.C.PosnerM.ZinnyM.A.A dose-response study of the efficacy and safety of" exact="ipratropium bromide" post="nasal spray in the treatment of the common coldJ"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7046835\results\search\drugs\results.xml">
   <result pre="venezuelan equine encephalitis virus nsP3 macro domains define a conserved" exact="adenosine" post="binding pocket. J Virol. (2009) 83:6534–45. 10.1128/JVI.00189-0919386706 90.RoundyCMAzarSRRossiSLWeaverSCVasilakisNChapter four"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7047929\results\search\drugs\results.xml">
   <result pre="201 ± 4 nm, with a monomodal size distribution and" exact="permethrin" post="content of 4.6 ± 0.1 mg/mL. It was observed"/>
   <result pre="407 Eugenol, 1,8-cineole, geraniol, linalool, carvacrol, α-terpineol, citronellol, thymol, and" exact="menthol" post="Diameter: Around 40 nm; Properties: Mortalities ranging from 30"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7048371\results\search\drugs\results.xml">
   <result pre="The catalytic (primary) site, which also binds inhibitors such as" exact="oseltamivir" post="carboxylate, is responsible for cleaving the sialic acid linkages"/>
   <result pre="various ligands suggested that both endogenous substrates and the drug" exact="oseltamivir" post="carboxylate bind faster to the 2° site than the"/>
   <result pre="are homologous to those within 5 Å of the crystallographic" exact="oseltamivir" post="carboxylate from the 2HU4 structure.12 PCA details, including indices"/>
   <result pre="suggest may play a role in the molecular mechanisms of" exact="oseltamivir" post="resistance,13 are also relatively flexible in the apo state."/>
   <result pre="allow negatively charged small molecules such as sialic acid or" exact="oseltamivir" post="carboxylate to move from the 2° site to the"/>
   <result pre="suggested electrostatic funneling as being the main driving force for" exact="oseltamivir" post="carboxylate association to the active site. Chloride anion and"/>
   <result pre="Structure-based design and synthesis of C-1- and C-4-modified analogs of" exact="zanamivir" post="as neuraminidase inhibitors. J. Med. Chem.2013, 56, 671–684. 10.1021/jm3009713.23330908"/>
   <result pre="Chem.2013, 56, 671–684. 10.1021/jm3009713.23330908 WenW. H.; et al. Analogs of" exact="zanamivir" post="with modified C4-substituents as the inhibitors against the group-1"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7049568\results\search\drugs\results.xml">
   <result pre="a majority of circulating viruses during 2008 became resistant to" exact="oseltamivir" post="prior to the 2009 pandemic.4, 5, 6, 7 Circulation"/>
   <result pre="viral polymerase inhibitor (baloxavir marboxil [Xofluza] approved in 2018).2,3,36 However," exact="amantadine" post="and its derivatives are no longer used because 100%"/>
   <result pre="old (Jackson Laboratories, Bar Harbor, ME, USA), were anesthetized with" exact="isoflurane" post="and administered (5 mice/group) 25 μg of 5′-PPP-NS1shRNA, capped-NS1shRNA,"/>
   <result pre="States—2017–2018 influenza seasonhttps://www.cdc.gov/flu/about/burden/2017-2018.htm2018 2HaydenF.G.AtmarR.L.SchillingM.JohnsonC.PoretzD.PaarD.HusonL.WardP.MillsR.G.Use of the selective oral neuraminidase inhibitor" exact="oseltamivir" post="to prevent influenzaN. Engl. J. Med.34119991336134310536125 3HeoY.A.Baloxavir: First Global"/>
   <result pre="and EFTA countries: an updateEuro Surveill.132008803218445425 5LackenbyA.HungnesO.DudmanS.G.MeijerA.PagetW.J.HayA.J.ZambonM.C.Emergence of resistance to" exact="oseltamivir" post="among influenza A(H1N1) viruses in EuropeEuro Surveill.132008802618445375 6HaugeS.H.DudmanS.BorgenK.LackenbyA.HungnesO.Oseltamivir-resistant influenza"/>
   <result pre="global seasonal influenza-associated respiratory mortality: a modelling studyLancet39120181285130029248255 36WendelH.A.SnyderM.T.PellS.Trial of" exact="amantadine" post="in epidemic influenzaClin. Pharmacol. Ther.7196638435325584 37collab: Centers for Disease"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7052542\results\search\drugs\results.xml">
   <result pre="in the neuraminidase and M2 genes that confer resistance to" exact="oseltamivir" post="and adamantanes were assessed. Fatal and nonfatal cases were"/>
   <result pre="increasing viral RNA loads on admission. Furthermore, the prevalence of" exact="amantadine" post="resistance–conferring M2 mutations increased over time, and viral loads"/>
   <result pre="(80%) and particularly in blood (85%), and antiviral responses to" exact="oseltamivir" post="appeared less pronounced. Conclusions These observations confirm the association"/>
   <result pre="and suggest potential differences in virulence and antiviral responses to" exact="oseltamivir" post="that may explain the exceptionally high mortality related to"/>
   <result pre="point to potential differences in virulence and antiviral responses to" exact="oseltamivir" post="that may explain the exceptionally high mortality related to"/>
   <result pre="loads, the presence of viremia, and a poor response to" exact="oseltamivir" post="treatment due to antiviral resistance [7–13]. Comparable data from"/>
   <result pre="detected in blood, and early antiviral responses to treatment with" exact="oseltamivir" post="appeared less pronounced when compared to Vietnamese H5N1 clade"/>
   <result pre="neuraminidase and matrix 2 (M2) genes that confer resistance to" exact="oseltamivir" post="and adamantanes, respectively, was analyzed using pyrosequencing or Sanger"/>
   <result pre="Figure 3). Figure 3. Viral RNA load and prevalence of" exact="amantadine" post="resistance over time. A, H5N1 RNA levels in admission"/>
   <result pre="of infection. Median value indicated in red. B, Prevalence of" exact="amantadine" post="resistance-conferring M2 mutations over time. Viral RNA was also"/>
   <result pre="respectively; P = .08). Response to Antiviral Treatment Treatment with" exact="oseltamivir" post="had a statistically significant impact on clinical outcome: 22"/>
   <result pre="days 4 and 5. Figure 4. Viral RNA load during" exact="oseltamivir" post="treatment. A, H5N1 RNA levels in serial throat swabs"/>
   <result pre="(black line) and surviving (dashed line) cases before and during" exact="oseltamivir" post="treatment. B, Changes in H5N1 RNA load from pretreatment"/>
   <result pre="red. Oseltamivir and Adamantane Resistance Mutations The presence of the" exact="oseltamivir" post="resistance–conferring His275Tyr (H275Y) substitution in neuraminidase (NA) was investigated"/>
   <result pre="168 pharyngeal samples collected from 78 patients after initiation of" exact="oseltamivir" post="treatment (Supplementary Table 1) and was not observed in"/>
   <result pre="contributed to the higher mortality among Indonesian patients. Treatment with" exact="oseltamivir" post="was associated with a survival benefit. This benefit was"/>
   <result pre="vs 18%), despite late treatment initiation in both [21]. Common" exact="oseltamivir" post="resistance–conferring neuraminidase mutations, including H275Y, R293K, and N295S [18],"/>
   <result pre="a range of other neuraminidase mutations reportedly associated with reduced" exact="oseltamivir" post="susceptibility in recently published whole-genome, next-generation sequencing data that"/>
   <result pre="known resistance mutations to explain the apparent limited benefit of" exact="oseltamivir" post="treatment in Indonesian patients. However, in vitro susceptibility testing"/>
   <result pre="2.1 viruses are intrinsically up to 30-fold less susceptible to" exact="oseltamivir" post="than clade 1 viruses [27]. Similar differences in oseltamivir"/>
   <result pre="to oseltamivir than clade 1 viruses [27]. Similar differences in" exact="oseltamivir" post="susceptibility between human seasonal influenza A and B viruses"/>
   <result pre="in Indonesian patients that show that, despite an absence of" exact="oseltamivir" post="resistance mutations, viral RNA was still detectable after 2"/>
   <result pre="limited, this might be explained by the aforementioned differences in" exact="oseltamivir" post="susceptibility. Changes in mortality were observed during the study"/>
   <result pre="in mice infected with isogenic recombinant H1N1 viruses that harbored" exact="amantadine" post="resistance mutations (Val27Ala, Ser31Gly, or both) was higher than"/>
   <result pre="29.KawaiN, IkematsuH, IwakiN, et al.A comparison of the effectiveness of" exact="oseltamivir" post="for the treatment of influenza A and influenza B:"/>
   <result pre="BoivinGGeneration and characterization of recombinant influenza A (H1N1) viruses harboring" exact="amantadine" post="resistance mutations. Antimicrob Agents Chemother2005; 49:556–9.15673732 33.PizzornoA, BouhyX, AbedY,"/>
   <result pre="neuraminidase inhibitors. J Infect Dis2011; 203:25–31.21148493 34.GrambasS, BennettMS, HayAJInfluence of" exact="amantadine" post="resistance mutations on the pH regulatory function of the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7054463\results\search\drugs\results.xml">
   <result pre="risk. Protein Expression: increase in production of potentially harmful neuronal" exact="nitric oxide" post="synthase (nNOS), reduction of reelin expression indicating abnormal neuronal"/>
   <result pre="young adults (P56) N/A Changes in the levels of neuronal" exact="nitric oxide" post="synthase (nNOS) involved in synaptogenesis and excitotoxicity: increase of"/>
   <result pre="offspring Deficient PPI; deficient responses to acute administration of clozapine," exact="chlorpromazine" post="and ketamine; deficient exploratory behavior in open-field and novel-object"/>
   <result pre="offspring of virally exposed mice at P14. No differences in" exact="dopamine" post="levels between exposed and control mice. A significant decrease"/>
   <result pre="levels between exposed and control mice. A significant decrease in" exact="dopamine" post="at P14 and P56 compared to P0 Asp et"/>
   <result pre="P7, P13 and P24. Transcripts encoding indoleamine-pyrrole 2,3-dioxygenase (IDO), degrading" exact="tryptophan" post="in the first step of the kynurenine pathway were"/>
   <result pre="receptor 2 in the frontal cortex (121), and decrease in" exact="dopamine" post="levels at P14 and P56 (115). Changes following poly(I:C)"/>
   <result pre="the GABAA and GABAB receptors, the AMPA receptor and the" exact="dopamine" post="D2 receptor; reviewed in (178)]. A potential association between"/>
   <result pre="M2 channel and NMDAR share a ligand, the antiviral compound" exact="amantadine" post="(198), suggesting putative structural homology which could form the"/>
   <result pre="studies are lacking, pilot studies in mice suggest that giving" exact="oseltamivir" post="to pregnant mice can prevent some influenza-induced changes in"/>
   <result pre="prevent some influenza-induced changes in the offspring (99). And while" exact="oseltamivir" post="is regarded as having a favourable profile in pregnancy,"/>
   <result pre="transcriptome signature in the adult offspring that is reversed by" exact="minocycline" post="treatment. Transl Psychiatry (2017) 7(5):e1120. 10.1038/tp.2017.8028485733 135LiWYChangYCLeeLJLeeLJPrenatal infection affects"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7054758\results\search\drugs\results.xml">
   <result pre="infect fresh HEK293T cells. HEK293T cells were selected with 5 μg/ml" exact="puromycin" post="(Sigma) 48 h after infection and then cultured for 1"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7055223\results\search\drugs\results.xml">
   <result pre="was collected at week ~7 post first immunization under terminal" exact="isoflurane" post="anesthesia followed by intracardiac puncture. Blood samples were collected"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7055873\results\search\drugs\results.xml">
   <result pre="was not found. One case with no prior history of" exact="oseltamivir" post="treatment possessed H275Y mutated virus in neuraminidase (NA), which"/>
   <result pre="H275Y mutated virus in neuraminidase (NA), which confers resistance to" exact="oseltamivir" post="and peramivir with elevated IC50 values. The full genome"/>
   <result pre="virus in neuraminidase (NA), which confers resistance to oseltamivir and" exact="peramivir" post="with elevated IC50 values. The full genome sequence of"/>
   <result pre="showed no mutations in neuraminidase (NA), which indicated susceptibility to" exact="oseltamivir" post="[8]. In July 2017, severe cases of influenza A(H1N1)pdm09"/>
   <result pre="for the mutation on NA gene that confers resistance to" exact="oseltamivir" post="was performed on the isolates using fluorescent-labeled chimeric RNA-DNA"/>
   <result pre="assay (NA inhibition assay) against four kinds of neuraminidase inhibitors," exact="oseltamivir" post="(Sequoia Research Products Ltd., Pangbourne, UK), zanamivir (Sequoia Research"/>
   <result pre="of neuraminidase inhibitors, oseltamivir (Sequoia Research Products Ltd., Pangbourne, UK)," exact="zanamivir" post="(Sequoia Research Products Ltd.), peramivir (Shionogi &amp;amp; Co., Ltd.,"/>
   <result pre="Research Products Ltd., Pangbourne, UK), zanamivir (Sequoia Research Products Ltd.)," exact="peramivir" post="(Shionogi &amp;amp; Co., Ltd., Osaka, Japan), and laninamivir (Daiichi"/>
   <result pre="°C, headache, runny nose, and myalgia. He did not receive" exact="oseltamivir" post="treatment prior to and after the medical visit. His"/>
   <result pre="the H275Y mutant A(H1N1)pdm09 virus has elevated IC50 value for" exact="oseltamivir" post="(301.5 nM with 198-fold increase) and peramivir (21.9 nM"/>
   <result pre="IC50 value for oseltamivir (301.5 nM with 198-fold increase) and" exact="peramivir" post="(21.9 nM with 274-fold increase) but not for zanamivir"/>
   <result pre="and peramivir (21.9 nM with 274-fold increase) but not for" exact="zanamivir" post="(0.58 nM with 0.9-fold difference) and laninamivir (0.72 nM"/>
   <result pre="of the reference drug-sensitive strain A/Perth/265/2009 (275H), indicating resistance to" exact="oseltamivir" post="and peramivir with highly reduced inhibition. All of the"/>
   <result pre="reference drug-sensitive strain A/Perth/265/2009 (275H), indicating resistance to oseltamivir and" exact="peramivir" post="with highly reduced inhibition. All of the remaining A(H1N1)pdm09"/>
   <result pre="with the reference strain A/Perth/265/2009 (275H) with IC50 values for" exact="oseltamivir" post="being 1.52nM, peramivir 0.08nM, zanamivir 0.62nM, laninamivir 0.27nM. Genetic"/>
   <result pre="strain A/Perth/265/2009 (275H) with IC50 values for oseltamivir being 1.52nM," exact="peramivir" post="0.08nM, zanamivir 0.62nM, laninamivir 0.27nM. Genetic characterization of HA"/>
   <result pre="(275H) with IC50 values for oseltamivir being 1.52nM, peramivir 0.08nM," exact="zanamivir" post="0.62nM, laninamivir 0.27nM. Genetic characterization of HA and NA"/>
   <result pre="27 in the M2 segment, which confers drug resistance to" exact="amantadine" post="[25]. Of note, the first oseltamivir-resistant strain in Myanmar"/>
   <result pre="the first case of oseltamivir-resistant virus in Myanmar without prior" exact="oseltamivir" post="treatment was detected in our study. In Myanmar, the"/>
   <result pre="for decades [25]. M2 gene mutations associated with resistance to" exact="amantadine" post="were found in only about 1% of V27A mutations"/>
   <result pre="of a H275Y mutation in NA that confer resistant to" exact="oseltamivir" post="from an influenza A(H1N1)pdm09 isolate in community samples of"/>
   <result pre="showed the S31N mutation in M2 that conferred resistance to" exact="amantadine" post="[8]. Oseltamivir was not previously used for the treatment"/>
   <result pre="were detected in community settings with no known exposure to" exact="oseltamivir" post="and the resistant virus spread within the community even"/>
   <result pre="high fold-increase in IC50 (198 and 274) to two NAIs," exact="oseltamivir" post="and peramivir. Global analysis on the susceptibility of human"/>
   <result pre="substitution was H275Y in A(H1N1)pdm09 viruses, which confers HRI by" exact="oseltamivir" post="and peramivir [41] without affecting the susceptibility to zanamivir"/>
   <result pre="H275Y in A(H1N1)pdm09 viruses, which confers HRI by oseltamivir and" exact="peramivir" post="[41] without affecting the susceptibility to zanamivir and laninamivir"/>
   <result pre="by oseltamivir and peramivir [41] without affecting the susceptibility to" exact="zanamivir" post="and laninamivir [42]. Despite the low prevalence of oseltamivir-resistance"/>
   <result pre="https://www.who.int/influenza/gisrs_laboratory/manual_diagnosis_surveillance_influenza/en/ 12SuzukiY, SaitoR, SatoI, ZaraketH, NishikawaM, TamuraT, et al.Identification of" exact="oseltamivir" post="resistance among pandemic and seasonal influenza A (H1N1) viruses"/>
   <result pre="and Singapore of a novel influenza A(H1N1)2009 variant with reduced" exact="oseltamivir" post="and zanamivir sensitivity due to a S247N neuraminidase mutation."/>
   <result pre="of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and" exact="zanamivir" post="sensitivity due to a S247N neuraminidase mutation. Euro Surveill."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7055907\results\search\drugs\results.xml">
   <result pre="1hr for virus adsorption, after which an overlay of 2.5%" exact="methylcellulose" post="was added and incubated for 5–10 days at 37°C"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7057477\results\search\drugs\results.xml">
   <result pre="only medications for symptomatic relief can be considered such as" exact="paracetamol" post="to relieve pain and fever associated with this infection"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7059726\results\search\drugs\results.xml">
   <result pre="and urine [12–14]. Also, increased levels of ROS and inducible" exact="nitric oxide" post="synthase (iNOS) have been observed as markers of oxidative"/>
   <result pre="metabolic changes by producing several mediators including indoleamine-2,3-dioxygenase (IDO) and" exact="nitric oxide" post="(NO), both of which appear to have either an"/>
   <result pre="inducible or an inhibitory role in viral replication [33]. Since" exact="tryptophan" post="is critical for T cell proliferation, depletion of this"/>
   <result pre="vitro and in vivo [107, 108], most likely through excessive" exact="nitric oxide" post="and other related free radicals [109]. In addition, increased"/>
   <result pre="with both increased activities of nucleotide catabolism core enzymes including" exact="adenosine" post="deaminase (ADA) and xanthine oxidase (XO) and elevated levels"/>
   <result pre="blockage of ACLY activity reduces the production of ROS and" exact="nitric oxide" post="[120]. There is a strong consensus that influenza replication"/>
   <result pre="induces production of kynurenine from L-tryptophan, thereby acting to deplete" exact="tryptophan" post="and modulate the immune system following viral infections [134]."/>
   <result pre="and establishes immune tolerance [136]. Indeed, an inhibitory effect of" exact="tryptophan" post="depletion on T cell responses has been confirmed. Also,"/>
   <result pre="the production of kynurenine from tryptophan. This event results in" exact="tryptophan" post="depletion, which in turn develops the immune tolerance and"/>
   <result pre="increased lymphocyte numbers in the respiratory tract [143]. IFNs and" exact="nitric oxide" post="induction Nitric oxide (NO) is a gaseous free radical"/>
   <result pre="metabolism by interleukin-1beta, but not by interleukin-6, is mediated by" exact="nitric oxide" post="in primary cultured rat hepatocytesBiochim Biophys Acta19961311202610.1016/0167-4889(95)00188-38603098 110.YaoMYaoDYamaguchiMChidaJYaoDKidoHBezafibrate upregulates"/>
   <result pre="humans and miceGene200739620321310.1016/j.gene.2007.04.01017499941 141.MellorALMunnDHIDO expression by dendritic cells: tolerance and" exact="tryptophan" post="catabolismNat Rev Immunol2004476277410.1038/nri145715459668 142.MunnDHMellorALIndoleamine 2,3 dioxygenase and metabolic control"/>
   <result pre="synthase in innate and adaptive immunity: an updateTrends Immunol20153616117810.1016/j.it.2015.01.00325687683 145.ReissCSKomatsuTDoes" exact="nitric oxide" post="play a critical role in viral infections?J Virol1998724547455110.1128/JVI.72.6.4547-4551.19989573217 146.UeharaEUShida"/>
   <result pre="critical role in viral infections?J Virol1998724547455110.1128/JVI.72.6.4547-4551.19989573217 146.UeharaEUShida BdeSde BritoCARole of" exact="nitric oxide" post="in immune responses against viruses: beyond microbicidal activityInflamm Res20156484585210.1007/s00011-015-0857-226208702"/>
   <result pre="activityInflamm Res20156484585210.1007/s00011-015-0857-226208702 147.AkaikeTNoguchiYIjiriSSetoguchiKSugaMZhengYMDietzscholdBMaedaHPathogenesis of influenza virus-induced pneumonia: involvement of both" exact="nitric oxide" post="and oxygen radicalsProc Natl Acad Sci1996932448245310.1073/pnas.93.6.24488637894 148.UetaniKDerSDZamanian-DaryoushMde la MotteCLiebermanBYWilliamsBRErzurumSCCentral"/>
   <result pre="role of double-stranded RNA-activated protein kinase in microbial induction of" exact="nitric oxide" post="synthaseJ Immunol200016598899610.4049/jimmunol.165.2.98810878375 149.ZakiMohammad HasanAkutaTeruoAkaikeTakaakiNitric Oxide-Induced Nitrative Stress Involved in"/>
   <result pre="Involved in Microbial PathogenesisJournal of Pharmacological Sciences200598211712910.1254/jphs.CRJ05004X15937405 150.AsanoKCheeCGastonBLillyCMGerardCDrazenJMStamlerJSConstitutive and inducible" exact="nitric oxide" post="synthase gene expression, regulation, and activity in human lung"/>
   <result pre="in human lung epithelial cellsProc Natl Acad Sci199491100891009310.1073/pnas.91.21.100897524082 151.GuoFHDe RaeveHRRiceTWStuehrDJThunnissenFErzurumSCContinuous" exact="nitric oxide" post="synthesis by inducible nitric oxide synthase in normal human"/>
   <result pre="Natl Acad Sci199491100891009310.1073/pnas.91.21.100897524082 151.GuoFHDe RaeveHRRiceTWStuehrDJThunnissenFErzurumSCContinuous nitric oxide synthesis by inducible" exact="nitric oxide" post="synthase in normal human airway epithelium in vivoProc Natl"/>
   <result pre="isoforms in macrophages are essential for NO homeostasisGenes Dev20102449150110.1101/gad.188141020194441 154.PerroneLABelserJAWadfordDAKatzJMTumpeyTMInducible" exact="nitric oxide" post="contributes to viral pathogenesis following highly pathogenic influenza virus"/>
   <result pre="highly pathogenic influenza virus infection in miceJ Infect Dis20132071576158410.1093/infdis/jit06223420903 155.DarwishIMillerCKainKCLilesWCInhaled" exact="nitric oxide" post="therapy fails to improve outcome in experimental severe influenzaInt"/>
   <result pre="Fouchier R, Osterhaus A. Inhibition of influenza virus replication by" exact="nitric oxide." post="In: International Congress Series: Elsevier; 2001. p. 551–5.. 157.TamuraDDeBiasiRLOkomo-AdhiamboMMishinVPCampbellAPLoecheltBWiedermannBLFryAMGubarevaLVEmergence"/>
   <result pre="child treated with Oseltamivir and ZanamivirJ Infect Dis20152121209121310.1093/infdis/jiv24525943200 158.DrakopoulosATzitzoglakiCMaCFreudenbergerKHoffmannAHuYGauglitzGNSchmidtkeMWangJKolocourisAAffinity of" exact="rimantadine" post="enantiomers against influenza A/M2 protein revisitedACS Med Chem Lett2017814515010.1021/acsmedchemlett.6b0031128217261"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7064921\results\search\drugs\results.xml">
   <result pre="mice. In a parallel study, targeted depletion of macrophages by" exact="clodronate" post="liposomes treatment in CHIKV�?infected mice yielded a similar outcome.13"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7066101\results\search\drugs\results.xml">
   <result pre="acute symptoms comes from findings that treatment with the antibiotic" exact="azithromycin" post="reduced the symptom burden of such episodes [46, 47],"/>
   <result pre="significant congenital heart disease (53% reduction) [68]. The application of" exact="palivizumab" post="resulted in a remarkably reduced risk of recurrent wheezing"/>
   <result pre="not asthma [11]. Interestingly, a new, second-generation high-affinity derivative of" exact="palivizumab" post="(motavizumab) did not prevent long-term recurrent wheezing despite reducing"/>
   <result pre="RSV disease [69]. Ribavirin There is no convincing data supporting" exact="ribavirin" post="treatment for severe RSV infection, while there are concerns"/>
   <result pre="RSV infection, while there are concerns about its toxicity. Therefore," exact="ribavirin" post="is neither recommended in the USA nor any European"/>
   <result pre="has been applied to wheezing children with RV etiology. Intriguingly," exact="prednisolone" post="application was shown to decrease the time to the"/>
   <result pre="In these recent randomized controlled trials, pre-term infants who received" exact="palivizumab" post="demonstrated a decreased number of recurrent wheezing episodes, but"/>
   <result pre="supports their use in combination with long-acting beta-agonists, such as" exact="salmeterol" post="and formoterol, and highlights the superiority of combination therapy"/>
   <result pre="in asthma exacerbations over either drug alone. Combination of either" exact="salmeterol" post="and fluticasone or budesonide and formoterol treatment in vitro"/>
   <result pre="exacerbations over either drug alone. Combination of either salmeterol and" exact="fluticasone" post="or budesonide and formoterol treatment in vitro has been"/>
   <result pre="either drug alone. Combination of either salmeterol and fluticasone or" exact="budesonide" post="and formoterol treatment in vitro has been shown to"/>
   <result pre="alone. Combination of either salmeterol and fluticasone or budesonide and" exact="formoterol" post="treatment in vitro has been shown to synergistically suppress"/>
   <result pre="markedly reduce infection-induced severe asthma exacerbations. A year-round treatment with" exact="omalizumab" post="has been shown to abolish the seasonal peaks in"/>
   <result pre="clinical benefit was associated with enhanced IFN-γ responses, suggesting that" exact="omalizumab" post="may improve the anti-viral responses [88]. Influenza vaccine Influenza"/>
   <result pre="United States and FinlandPediatr Infect Dis J2019383e59e6210.1097/INF.000000000000214130001231 21.EsquivelABusseWWCalatroniATogiasAGGrindleKGBochkovYAGruchallaRSKattanMKercsmarCMKhurana HersheyGKimHLebeauPLiuAHSzeflerSJTeachSJWestJBWildfireJPongracicJAGernJEEffects of" exact="omalizumab" post="on rhinovirus infections, illnesses, and exacerbations of asthmaAm J"/>
   <result pre="a randomised, double-blind, placebo-controlled trialLancet Respir Med201641192610.1016/S2213-2600(15)00500-726704020 47.BacharierLBGuilbertTWMaugerDTBoehmerSBeigelmanAFitzpatrickAMJacksonDJBaxiSNBensonMBurnhamCDCabanaMCastroMChmielJFCovarRDainesMGaffinJMGentileDAHolguinFIsraelEKellyHWLazarusSCLemanskeRFJrLyNMeadeKMorganWMoyJOlinTPetersSPPhipatanakulWPongracicJARaissyHHRossKSheehanWJSorknessCSzeflerSJTeagueWGThyneSMartinezFDEarly administration of" exact="azithromycin" post="and prevention of severe lower respiratory tract illnesses in"/>
   <result pre="of asthmaJ Allergy Clin Immunol201012561178118710.1016/j.jaci.2010.04.02120513517 72.JarttiTNieminenRVuorinenTLehtinenPVahlbergTGernJCamargoCAJrRuuskanenOShort- and long-term efficacy of" exact="prednisolone" post="for first acute rhinovirus-induced wheezing episodeJ Allergy Clin Immunol2015135369169810.1016/j.jaci.2014.07.00125129681"/>
   <result pre="response to infection with rhinovirusJ Exp Med2005201693794710.1084/jem.2004190115781584 84.BusseWWMorganWJGergenPJMitchellHEGernJELiuAHGruchallaRSKattanMTeachSJPongracicJAChmielJFSteinbachSFCalatroniATogiasAThompsonKMSzeflerSJSorknessCARandomized trial of" exact="omalizumab" post="(anti-IgE) for asthma in inner-city childrenN Engl J Med2011364111005101510.1056/NEJMoa100970521410369"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7068796\results\search\drugs\results.xml">
   <result pre="Plasmodium falciparum PfEMP1 erythrocyte membrane protein, which interacts with the" exact="chondroitin sulfate" post="antigen of the placenta matrix (35). While this binding"/>
   <result pre="126.MoreiraMLCosta-PereiraCAlvesMLRMarteletoBHRibeiroVMPeruhype-MagalhãesVet al.. Vaccination against canine leishmaniosis increases the phagocytic activity," exact="nitric oxide" post="production and expression of cell activation/migration molecules in neutrophils"/>
   <result pre="Immunol Immunopathol. (2010) 135:296–302. 10.1016/j.vetimm.2009.12.00820132994 129.AraújoMSSde AndradeRASathler-AvelarRTeixeira-CarvalhoAAndradeMCViannaLRet al.. T-cell-derived cytokines," exact="nitric oxide" post="production by peripheral blood monocytes and seric anti-Leishmania (Leishmania)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7071112\results\search\drugs\results.xml">
   <result pre="vaginal discharge syndromes, patients are treated with ceftriaxone, azithromycin, and" exact="metronidazole" post="per national guidelines. Additional doses of azithromycin, and extended"/>
   <result pre="metronidazole per national guidelines. Additional doses of azithromycin, and extended" exact="metronidazole" post="in women, are recommended for scrotal swelling and lower"/>
   <result pre="scrotal swelling and lower abdominal pain syndromes, respectively. Erythromycin or" exact="doxycycline" post="is substituted when azithromycin is unavailable. Integrated cervical cancer"/>
   <result pre="abdominal pain syndromes, respectively. Erythromycin or doxycycline is substituted when" exact="azithromycin" post="is unavailable. Integrated cervical cancer screening is offered to"/>
   <result pre="way allows for antibiotics to target specific infections, such as" exact="azithromycin" post="alone for CT, rather than providing syndromic treatment for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7074809\results\search\drugs\results.xml">
   <result pre="used alone or in combination. An example of this is" exact="ribavirin" post="and interferon α. Indeed, there is little literature on"/>
   <result pre="ErsoyE.TanrioverM.D.OcalS.OzisikL.InkayaC.TopeliA.Severe measles pneumonia in adults with respiratory failure: Role of" exact="ribavirin" post="and high-dose vitamin AClin. Respir. J.20161067367510.1111/crj.1226925619709 94.WydeP.R.Chemotherapy of respiratory"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7075273\results\search\drugs\results.xml">
   <result pre="37.8°C. She received oral cortical hormone (30 mg daily) and" exact="tacrolimus" post="for 19 months to control the suspected chronic GVHD."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7076820\results\search\drugs\results.xml">
   <result pre="al. found that four organic acids (syringic acid, 2-amino-benzoic acid," exact="salicylic acid," post="benzoic acid) from Radix isatidis could inhibit the growth"/>
   <result pre="fetal bovine serum (HyClone, UT, USA), 100 U/mL penicillin, and 100 U/mL" exact="streptomycin" post="(HyClone, UT, USA) at 37 °C with 5% CO2. Determination"/>
   <result pre="pseudorabies virus genomeJ Virol200478142444010.1128/JVI.78.1.424-440.200414671123 5.SuiXYinJRenXAntiviral effect of diammonium glycyrrhizinate and" exact="lithium" post="chloride on cell infection by pseudorabies herpesvirusAntivir Res201085234635310.1016/j.antiviral.2009.10.01419879899 6.MullerTHahnECTottewitzFKramerMKluppBGMettenleiterTCFreulingCPseudorabies"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7076942\results\search\drugs\results.xml">
   <result pre="gene expression (Table 1). Conversely, Staphylococcus had negative correlations with" exact="tetracycline" post="resistance gene expression (Table 2). Metatranscriptomic reads that mapped"/>
   <result pre="from the 16S rRNA gene data was negatively correlated with" exact="tetracycline" post="resistance gene expression. We also observed previously unreported correlations"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7077231\results\search\drugs\results.xml">
   <result pre="Sigma-Aldrich), 200 U/mL penicillin (Life Technologies, Carlsbad, CA), 200 μg/mL" exact="streptomycin" post="(Life Technologies), 5 μg/mL fungizone (Life Technologies); and filter"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7077299\results\search\drugs\results.xml">
   <result pre="For viral infections, guinea pigs were anesthetized intraperitoneally (i.p.) with" exact="ketamine" post="(30 mg/kg) and xylazine (5 mg/kg) and inoculated intranasally"/>
   <result pre="endonuclease inhibitor baloxavir marboxilSci. Rep.20188963310.1038/s41598-018-27890-429941893 26.HeG.MassarellaJ.WardP.Clinical pharmacokinetics of the prodrug" exact="oseltamivir" post="and its active metabolite Ro 64-0802Clin. Pharmacokinet.19993747148410.2165/00003088-199937060-0000310628898 27.DaviesB.E.Pharmacokinetics of"/>
   <result pre="prophylaxis of influenza in diverse populationsJ. Antimicrob. Chemother.201065ii5ii1010.1093/jac/dkq01520215135 28.HoradamV.W.SharpJ.G.SmilackJ.D.McAnalleyB.H.GarriottJ.C.StephensM.K.PratiR.C.BraterD.C.Pharmacokinetics of" exact="amantadine" post="hydrochloride in subjects with normal and impaired renal functionAnn."/>
   <result pre="transiently expressed recombinant proteinPlant. Biotechnol. J.2015131169117910.1111/pbi.1245226286859 58.NicholsonK.G.AokiF.Y.OsterhausA.D.TrottierS.CarewiczO.MercierC.H.RodeA.KinnersleyN.WardP.Efficacy and safety of" exact="oseltamivir" post="in treatment of acute influenza: A randomised controlled trial."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7077973\results\search\drugs\results.xml">
   <result pre="PrEP and PEP.8–10 In 2015, a pilot study of daily" exact="doxycycline" post="as syphilis PrEP in HIV-positive gbMSM in Los Angeles"/>
   <result pre="compared with a contingency management intervention.9,11 Another randomized trial assessed" exact="doxycycline" post="as STI PEP versus no intervention in 232 HIV-negative"/>
   <result pre="doxycycline-based PrEP was lower, at 44.1%. Because the definitions of" exact="doxycycline" post="PEP and PrEP provided to participants only differed in"/>
   <result pre="trial of combined syphilis and HIV PrEP using both daily" exact="doxycycline" post="and tenofovir disoproxil fumarate/emtricitabine, with final results expected in"/>
   <result pre="combined syphilis and HIV PrEP using both daily doxycycline and" exact="tenofovir" post="disoproxil fumarate/emtricitabine, with final results expected in summer/fall 2020.24"/>
   <result pre="affordable drug used in the treatment of many common infections," exact="doxycycline" post="is already publicly covered in both Ontario and British"/>
   <result pre="concept of antimicrobial resistance, this knowledge was not associated with" exact="doxycycline" post="PrEP and PEP acceptability. However, the potential for long-term"/>
   <result pre="doxycycline PrEP and PEP acceptability. However, the potential for long-term" exact="doxycycline" post="use to induce resistance in both normal host flora"/>
   <result pre="a joint policy statement warning that the potential benefit of" exact="doxycycline" post="PEP for STIs would be outweighed by the risk"/>
   <result pre="STI PrEP or PEP have formally evaluated the emergence of" exact="tetracycline" post="class resistance in host normal flora, and the limited"/>
   <result pre="data from Neisseria gonorrhoeae and C. trachomatis isolates in the" exact="doxycycline" post="PEP trial has suggested no increase in resistance or"/>
   <result pre="Available at: https://www.canada.ca/content/dam/phac-aspc/documents/services/publications/diseases-conditions/report-sexually-transmitted-infections-canada-2013-14/report-sexually-transmitted-infections-canada-2013-14-eng.pdf. Accessed December 13, 2018. 4HottesTSLesterRTHoangLMet al.Cephalosporin and" exact="azithromycin" post="susceptibility in Neisseria gonorrhoeae isolates by site of infection,"/>
   <result pre="pilot study. Sex Transm Dis2015; 42:98–103.25585069 10MolinaJMCharreauIChidiacCet al.Post-exposure prophylaxis with" exact="doxycycline" post="to prevent sexually transmitted infections in men who have"/>
   <result pre="gay men. Sex Transm Dis2011; 38:573–579.21343845 20SpinelliMAScottHVittinghoffEet al.High interest in" exact="doxycycline" post="for sexually transmitted infection post-exposure prophylaxis (doxy-PEP) in a"/>
   <result pre="British Association for Sexual Health and HIV. Position statement on" exact="doxycycline" post="as post-exposure prophylaxis for sexually transmitted infections. Available at:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7081911\results\search\drugs\results.xml">
   <result pre="catalog no. 21969035) supplemented with 10% fetal calf serum, 2 mM" exact="l-glutamine" post="(Gibco, catalog no. 25030081), and 50 U/ml penicillin and"/>
   <result pre="(Gibco, catalog no. 25030081), and 50 U/ml penicillin and 50 μg/ml" exact="streptomycin" post="(Gibco, catalog no. 15140122). The specific use of the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7084951\results\search\drugs\results.xml">
   <result pre="immune competence mediated by seasonal factors, such as levels of" exact="melatonin" post="[38]; seasonality-related behavioral factors, such as school attendance and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7092853\results\search\drugs\results.xml">
   <result pre="Economic and Technological Development Zone, China), was dissolved in 100%" exact="dimethyl sulfoxide" post="(DMSO) as a 20 mM stock solution and stored"/>
   <result pre="infection period, the cells were overlaid with DMEM containing 1.5%" exact="methylcellulose" post="and 2% FBS, and then incubated for two days."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7094151\results\search\drugs\results.xml">
   <result pre="considerations include sialic acid analogs, cold atmospheric plasma, N-chlorotaurine, and" exact="benzalkonium chloride." post="Continued investigation and evaluation of treatment are warranted to"/>
   <result pre="use in clinical the clinical setting.30 However, combining iodine with" exact="povidone" post="allowed for this antiseptic to be safely and routinely"/>
   <result pre="ophthalmic gel, interferon eye drops, a tobramycin-dexamethasone combo, and topical" exact="diclofenac" post="sodium. In this study, interferon was administered with the"/>
   <result pre="side effects, such as inflammation, congestion, and edema, tobramycin-dexamethasone and" exact="diclofenac" post="sodium treatments were also employed. This combination of drugs"/>
   <result pre="a challenge in the treatment of adenoviral keratoconjunctivitis.47 Ribavirin and" exact="cidofovir" post="have also been shown to exhibit antiviral activity against"/>
   <result pre="polymerase, causing viral DNA chain termination and viral inhibition.13,44 Intravenous" exact="cidofovir" post="is often used in transplant clinics with only mild"/>
   <result pre="ocular toxicity around the skin of eyelids and conjunctiva.46 Similarly," exact="ribavirin" post="also results in poor systemic side effects and safety"/>
   <result pre="infiltrates. This study showed great promise in the future of" exact="cidofovir" post="for the treatment of ocular HAdV infections in the"/>
   <result pre="therapeutic use. Gordon et al described the effects of topical" exact="cidofovir" post="in uninfected animals, determining that there was consistent clinically"/>
   <result pre="Even at lower and presumably ineffective dosages, 3.5 mg of" exact="cidofovir" post="continued exhibit significant ocular surface toxicity in vivo.52 Resistance"/>
   <result pre="to be an ophthalmic form.13,44 When antiviral comparison is made," exact="ganciclovir" post="appears to be the most favorable in terms of"/>
   <result pre="Nwanegbo et al found that Ig was actually comparable to" exact="cidofovir" post="in its antiviral activity. While cidofovir acts intracellularly to"/>
   <result pre="was actually comparable to cidofovir in its antiviral activity. While" exact="cidofovir" post="acts intracellularly to block DNA replication, Ig neutralizes the"/>
   <result pre="neutralizes the virus on the ocular surface. In comparison to" exact="cidofovir" post="and saline titers, Ig was more effective during the"/>
   <result pre="be beneficial in prophylaxis to prevent clinical infections. Though both" exact="cidofovir" post="and Ig were effective in this study, cidofovir demonstrated"/>
   <result pre="Though both cidofovir and Ig were effective in this study," exact="cidofovir" post="demonstrated a significantly shorter duration of viral shedding. This"/>
   <result pre="be helpful in such cases.63 In a study comparing topical" exact="loteprednol" post="with dexamethasone, similar outcomes in SEI treatment were observed."/>
   <result pre="the first to investigate NSAID effects on adenoviral replication, specifically" exact="ketorolac" post="tromethamine and diclofenac sodium ophthalmic solutions. During both the"/>
   <result pre="investigate NSAID effects on adenoviral replication, specifically ketorolac tromethamine and" exact="diclofenac" post="sodium ophthalmic solutions. During both the early and late"/>
   <result pre="did it affect the duration of viral shedding. In contrast," exact="prednisolone" post="treatment was shown to prolong viral shedding.73 As it"/>
   <result pre="viral shedding.73 As it pertained to sub-epithelial infiltrates, treatment with" exact="diclofenac" post="or ketorolac did not yield a statistically significant reduction"/>
   <result pre="As it pertained to sub-epithelial infiltrates, treatment with diclofenac or" exact="ketorolac" post="did not yield a statistically significant reduction when compared"/>
   <result pre="a statistically significant reduction when compared to control groups, whereas" exact="prednisolone" post="did. This study suggests that NSAIDs are not likely"/>
   <result pre="of using corticosteroids or to limit associated corticosteroid complications. Topical" exact="cyclosporine" post="(both 1% and 2% concentrations) is an alternative option"/>
   <result pre="3–4 weeks.64,66,69,78 Okumus et al studied the efficacy of 0.05%" exact="cyclosporine" post="(Restasis®, Allergan, Irvine, California, USA) once per day or"/>
   <result pre="due to subsequent, elevated IOP. After one month of 0.05%" exact="cyclosporine" post="treatment, 81.75% of eyes had cleared SEIs while the"/>
   <result pre="treatment options for acute adenoviral keratoconjunctivitis using either topical 1%" exact="prednisolone" post="acetate in conjunction with non-preserved artificial tears, topical 2%"/>
   <result pre="In comparison to artificial tears alone, both the corticosteroid and" exact="cyclosporine" post="groups exhibited improvement in symptoms as well as a"/>
   <result pre="well as a shorter duration. Both the Cyclosporine A and" exact="prednisolone" post="groups were also similarly effective in preventing the development"/>
   <result pre="to prevent rejection in organ transplants. However, despite similar effects," exact="tacrolimus" post="and cyclosporine differ in their chemical makeup. Cyclosporine is"/>
   <result pre="rejection in organ transplants. However, despite similar effects, tacrolimus and" exact="cyclosporine" post="differ in their chemical makeup. Cyclosporine is a cyclic"/>
   <result pre="calcineurin inhibitors, an enzyme necessary for T cell replication.82,83 When" exact="cyclosporine" post="and tacrolimus enter T cells, they bind to their"/>
   <result pre="an enzyme necessary for T cell replication.82,83 When cyclosporine and" exact="tacrolimus" post="enter T cells, they bind to their respective immunophilins,"/>
   <result pre="survival of CD4+ T cells and CD8+ T cells.70,84-86 Topical" exact="tacrolimus" post="0.03% has ophthalmic uses, mainly in the treatment of"/>
   <result pre="vernal keratoconjunctivitis. With regards to its effect on HAdV keratoconjunctivitis," exact="tacrolimus" post="was more effective than dexamethasone in the reduction of"/>
   <result pre="its effect on HAdV keratoconjunctivitis, tacrolimus was more effective than" exact="dexamethasone" post="in the reduction of SEIs, and subsequently in the"/>
   <result pre="of vision and symptomology. This study is significant in that" exact="tacrolimus" post="was not only superior to topical corticosteroids in the"/>
   <result pre="Generally, for SEIs that are resistant to tapering of corticosteroid," exact="tacrolimus" post="0.03% was proven to be an effective corticosteroid-sparing agent.87"/>
   <result pre="antiviral use appears to be synergistic and efficacious.44 Cardiotonic steroids" exact="digoxin" post="and digitoxin have been suggested to offer a new"/>
   <result pre="appears to be synergistic and efficacious.44 Cardiotonic steroids digoxin and" exact="digitoxin" post="have been suggested to offer a new strategy to"/>
   <result pre="ATPase is an important cell signaling molecule, where binding with" exact="digoxin" post="or digitoxin initiates multiple signaling cascades, influencing gene expression."/>
   <result pre="an important cell signaling molecule, where binding with digoxin or" exact="digitoxin" post="initiates multiple signaling cascades, influencing gene expression. These drugs"/>
   <result pre="viral shedding.52 When comparing PVI/dexamethasone combination treatment with that of" exact="dexamethasone" post="alone, combination drops not only increase recovery but also,"/>
   <result pre="sialic acid analogs, cold atmospheric plasma (CAP), N-chlorotaurine, and even" exact="benzalkonium chloride" post="(BAK). Sialic acid plays a role in initial attachment"/>
   <result pre="rare cases of lacrimal canalicularblockade in rabbit models.107 Ganciclovir 3%" exact="ganciclovir" post="reduced HAdV 5 replication and pathogenesis in animal models.108"/>
   <result pre="EKC symptoms and Persistent adenoviral SEIs.2,63 Glaucoma and cataracts.116 Topical" exact="cyclosporine" post="Effective against persistent adenoviral SEIs.66,69,117–119 Transient or long-lasting burning"/>
   <result pre="ocular pain/irritation, redness; eyelid swelling in Steven Johnsons patients.121 Topical" exact="tacrolimus" post="Superior to dexamethasone in reducing symptomology and SEIs70 as"/>
   <result pre="eyelid swelling in Steven Johnsons patients.121 Topical tacrolimus Superior to" exact="dexamethasone" post="in reducing symptomology and SEIs70 as well as a"/>
   <result pre="ganciclovir, cidofovir, PVI irrigation Poor bioavailability and high toxicity of" exact="cidofovir" post="Lipid-linked derivative brincidofovir and potential development of ophthalmic formulation"/>
   <result pre="(ie, elevated IOP and cataract formation) Immunotherapy such as topical" exact="cyclosporine" post="or tacrolimus Corticosteroids prolonging viral shedding Combination PVI/dexamethasone ophthalmic"/>
   <result pre="IOP and cataract formation) Immunotherapy such as topical cyclosporine or" exact="tacrolimus" post="Corticosteroids prolonging viral shedding Combination PVI/dexamethasone ophthalmic solution Conjunctival"/>
   <result pre="2008;34(6):845–855. doi:10.1016/j.burns.2007.11.01418378399 34.YazarH, YarbagA, BalciM, TekerB, TanyeriP. The effects of" exact="povidone" post="iodine (pH 4.2) on patients with adenoviral conjunctivitis. J"/>
   <result pre="42.KimSJ, KimK, ParkSB, HongDJ, JhunBW. Outcomes of early administration of" exact="cidofovir" post="in non-immunocompromised patients with severe adenovirus pneumonia. PLoS One."/>
   <result pre="BoeckhM. Adenovirus infection in hematopoietic stem cell transplantation: effect of" exact="ganciclovir" post="and impact on survival. Biol Blood Marrow Transplant. 2003;9(5):341–352."/>
   <result pre="Marrow Transplant. 2003;9(5):341–352. doi:10.1016/S1083-8791(03)00102-212766884 46.HuangJ, KadonosonoK, UchioE. Antiadenoviral effects of" exact="ganciclovir" post="in types inducing keratoconjunctivitis by quantitative polymerase chain reaction"/>
   <result pre="doi:10.1016/0166-3542(95)00962-08811201 49.RomanowskiEG, YatesKA, GordonYJ. Antiviral prophylaxis with twice daily topical" exact="cidofovir" post="protects against challenge in the adenovirus type 5/New Zealand"/>
   <result pre="al. Clinical and antiviral efficacy of an ophthalmic formulation of" exact="dexamethasone" post="povidone-iodine in a rabbit model of adenoviral keratoconjunctivitis. Invest"/>
   <result pre="2000;19(1):69–85. doi:10.1016/S1350-9462(99)00004-X10614681 64.HillenkampJ, ReinhardT, RossRS, et al. The effects of" exact="cidofovir" post="1% with and without cyclosporin a 1% as a"/>
   <result pre="et al. Topical treatment of acute adenoviral keratoconjunctivitis with 0.2%" exact="cidofovir" post="and 1% cyclosporine: a controlled clinical pilot study. Arch"/>
   <result pre="doi:10.1001/archopht.119.10.148711594949 66.LevingerE, SlomovicA, SansanayudhW, BaharI, SlomovicAR. Topical treatment with 1%" exact="cyclosporine" post="for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis. Cornea. 2010;29(6):638–640."/>
   <result pre="pilot study]. Ophthalmologe. 2000;97(11):764–768. German. doi:10.1007/s003470070025.11130165 68.KilicA, GurlerB. Topical 2%" exact="cyclosporine" post="A in preservative-free artificial tears for the treatment of"/>
   <result pre="of the safety and efficacy of topical Tacrolimus (0.03%) versus" exact="dexamethasone" post="(0.05%) for subepithelial infiltrates after adenoviral conjunctivitis. Indian J"/>
   <result pre="CevherS, MatE. Symptomatic treatment of subepithelial infiltrates after viral conjunctivitis:" exact="loteprednol" post="or dexamethasone?Ocul Immunol Inflamm. 2017;25(5):649–653. doi:10.3109/09273948.2016.114959327015587 72.AsenaL, Singar OzdemirE,"/>
   <result pre="uses. Surv Ophthalmol. 1986;31(3):159–169. doi:10.1016/0039-6257(86)90035-43544293 78.RomanowskiEG, PlessP, YatesKA, GordonYJ. Topical" exact="cyclosporine" post="A inhibits subepithelial immune infiltrates but also promotes viral"/>
   <result pre="experimental adenovirus models. Cornea. 2005;24(1):86–91. doi:10.1097/01.ico.0000127481.23714.b615604872 79.LiegnerJT, YeeRW, WildJH. Topical" exact="cyclosporine" post="therapy for ulcerative keratitis associated with rheumatoid arthritis. Am"/>
   <result pre="inflammatory disease. Cornea. 1993;12(5):413–419. doi:10.1097/00003226-199309000-000088306663 81.PerryHD, Doshi-carnevaleS, DonnenfeldED, KornsteinHS. Topical" exact="cyclosporine" post="A 0.5% as a possible new treatment for superior"/>
   <result pre="Pharmacokinet. 1993;24(6):472–495. doi:10.2165/00003088-199324060-000048513650 83.ThomsonAW, BonhamCA, ZeeviA. Mode of action of" exact="tacrolimus" post="(FK506): molecular and cellular mechanisms. Ther Drug Monit. 1995;17(6):584–591."/>
   <result pre="Monit. 1995;17(6):584–591. doi:10.1097/00007691-199512000-000078588225 84.BarbarinoJM, StaatzCE, VenkataramananR, KleinTE, AltmanRB. PharmGKB summary:" exact="cyclosporine" post="and tacrolimus pathways. Pharmacogenet Genomics. 2013;23(10):563–585. doi:10.1097/FPC.0b013e328364db8423922006 85.BoymanO, SprentJ."/>
   <result pre="doi:10.1097/00007691-199512000-000078588225 84.BarbarinoJM, StaatzCE, VenkataramananR, KleinTE, AltmanRB. PharmGKB summary: cyclosporine and" exact="tacrolimus" post="pathways. Pharmacogenet Genomics. 2013;23(10):563–585. doi:10.1097/FPC.0b013e328364db8423922006 85.BoymanO, SprentJ. The role"/>
   <result pre="of adenoviral keratoconjunctivitis with a combination of povidone-iodine 1.0% and" exact="dexamethasone" post="0.1% drops: a clinical prospective controlled randomized study. Acta"/>
   <result pre="PhillipsJ, NarendranN, YangYC. Ocular surface effects of repeated application of" exact="povidone" post="iodine in patients receiving frequent intravitreal injections. Cutan Ocul"/>
   <result pre="with human type 5 adenovirus in immunosuppressed Syrian hamsters, while" exact="ribavirin" post="is largely ineffective in this model. Antiviral Res. 2014;112:38–46."/>
   <result pre="Cornea. 2011;30(9):958–961. doi:10.1097/ICO.0b013e31820cd60721673568 118.MuftuogluIK, AkovaYA, GungorSG. Effect of 0.05% topical" exact="cyclosporine" post="for the treatment of symptomatic subepithelial infiltrates due to"/>
   <result pre="119.BayraktutarBN, UcakhanOO. Comparison of efficacy of two different topical 0.05%" exact="cyclosporine" post="a formulations in the treatment of adenoviral keratoconjunctivitis-related subepithelial"/>
   <result pre="CaputoR, MoriF, et al. Long-term safety and efficacy of topical" exact="cyclosporine" post="in 156 children with vernal keratoconjunctivitis. Int J Immunopathol"/>
   <result pre="J Immunopathol Pharmacol. 2010;23(3):865–871. doi:10.1177/03946320100230032220943058 121.SchultzC. Safety and efficacy of" exact="cyclosporine" post="in the treatment of chronic dry eye. Ophthalmol Eye"/>
   <result pre="Eye Dis. 2014;6:37–42. doi:10.4137/OED.S1606725002818 122.LevingerE, TrivizkiO, ShacharY, LevingerS, TopicalVD. 0.03%" exact="tacrolimus" post="for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis. Graefes Arch"/>
   <result pre="Riestra AyoraAC, Lisa FernandezC, Chacon RodriguezM, Merayo-llovesJ, Alfonso SanchezJF. Topical" exact="tacrolimus" post="for corneal subepithelial infiltrates secondary to adenoviral keratoconjunctivitis. Cornea."/>
   <result pre="124.BarotRK, ShitoleSC, BhagatN, PatilD, SawantP, PatilK. Therapeutic effect of 0.1%" exact="tacrolimus" post="eye ointment in allergic ocular diseases. J Clin Diagn"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7098447\results\search\drugs\results.xml">
   <result pre="was defined as at least a dose (≥ 0.5 mg/kg) of" exact="methylprednisolone" post="during hospitalization (26, 27). Statistical Analysis Continuous data were"/>
   <result pre="failure, and rhabdomyolysis and with rapid recovery after treatment with" exact="oseltamivir" post="and intra-aortic balloon pump support.Cardiovasc Revasc Med2018; 19:374229113868 29.LudwigALucero-ObusanCSchirmerPet"/>
   <result pre="hemodynamic study.Am J Pathol1990; 136:4094192154929 35.RayCGIcenogleTBMinnichLLet al.The use of intravenous" exact="ribavirin" post="to treat influenza virus-associated acute myocarditis.J Infect Dis1989; 159:8298362775346"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7098917\results\search\drugs\results.xml">
   <result pre="China. Infect Genet Evol. (2013) 14:444–9. 10.1016/j.meegid.2012.11.01823261544 71.YangGLiSBlackmonSYeJBradleyKCCooleyJet al.. Mutation" exact="tryptophan" post="to leucine at position 222 of haemagglutinin could facilitate"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7099755\results\search\drugs\results.xml">
   <result pre="states that the respective resistance rates to penicillin, cefuroxime, and" exact="erythromycin" post="are 53.6%, 46.4%, and as high as 94.2% in"/>
   <result pre="GilliganP, CohenMS. Breakthrough pneumococcal bacteremia in patients being treated with" exact="azithromycin" post="and clarithromycin. Clin Infect Dis. 2000;31(4):1008�?1011.11049784 47EversS, AmentA, ColomboGL,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7100926\results\search\drugs\results.xml">
   <result pre="Transcriptase Inhibitors than in Protease Inhibitors. Emtricitabine, lamivudine, efavirenz, and" exact="nevirapine" post="were the antiretroviral drugs with the most resistance. Supporting"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7100975\results\search\drugs\results.xml">
   <result pre="167 0 1 (1.15) 1.15 [-1.09;3.39] 1** Cumulative dose of" exact="paracetamol" post="since the beginning of symptoms (milligrams) 83 5.57 (4.48)#"/>
   <result pre="the production of pro�?inflammatory cytokines by monocytes [50,51] and that" exact="estradiol" post="plays a role in the increase of antibody production"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7102570\results\search\drugs\results.xml">
   <result pre="cures all mice in a lethal influenza infection model, while" exact="oseltamivir" post="fails to cure the animals. Thus, favipiravir contributes to"/>
   <result pre="2009). Favipiravir shows better efficacy in treating influenza infections than" exact="oseltamivir" post="(Tamiflu) (Takahashi et al., 2003; Tanaka et al., 2017),"/>
   <result pre="Guanosine, inosine, and AICAR are biosynthesized in the body, and" exact="ribavirin" post="and ribosyl favipiravir are synthesized nucleoside analogues. They have"/>
   <result pre="influenza A(H7N9) (Li et al., 2014). A combination therapy with" exact="oseltamivir" post="has been used to treat patients with severe influenza"/>
   <result pre="and conducted experiments to compare the efficacy of favipiravir with" exact="oseltamivir" post="(Tamiflu). Based on its chemical structure, favipiravir should inhibit"/>
   <result pre="in Japan (Yasukawa, 2016) and as a combination therapy with" exact="oseltamivir" post="to treat patients with severe influenza in China (Cao,"/>
   <result pre="(EC50 = 63.7 μM) of adenine, guanine, adenosine, guanosine, and" exact="inosine" post="in the assay medium abolishes the anti-influenza virus activity"/>
   <result pre="1998; Kurokawa, Brown, Kagawa, &amp;amp; Shiraki, 2003). Cinnamyl compounds and" exact="clarithromycin" post="increase the levels of IL-12 on day 2 and"/>
   <result pre="we have experience in conducting a pharmacological study for a" exact="famciclovir" post="approval application in Japan, the efficacy and validation studies"/>
   <result pre="shows one of the comparisons of efficacy between favipiravir and" exact="oseltamivir" post="in the influenza virus infection model established with a"/>
   <result pre="of experiments, and the better efficacy of favipiravir compared with" exact="oseltamivir" post="was observed in an animal with a severe lethal"/>
   <result pre="a high viral load (Takahashi et al., 2003). Favipiravir and" exact="oseltamivir" post="show similar efficacy in low-dose infections, but the efficacy"/>
   <result pre="favipiravir as an influenza drug is clearly increased compared with" exact="oseltamivir" post="in high-titer virus infections (Fig. 3). Mice in the"/>
   <result pre="die on day 3 after a high-dose infection, and an" exact="oseltamivir" post="treatment prolongs the survival period for three days but"/>
   <result pre="infection, and all mice survive. Favipiravir exhibits better efficacy than" exact="oseltamivir" post="after a delayed administration beginning 1, 24, 48, or"/>
   <result pre="2003). Fig. 3 Comparison of the efficacy of favipiravir and" exact="oseltamivir" post="in lethal influenza virus infection. Mice were infected with"/>
   <result pre="of influenza A/PR/8/34 virus and were orally administered favipiravir and" exact="oseltamivir" post="at doses of 200 and 400 mg/kg/day for 5"/>
   <result pre="from a representative experiment. *P &amp;lt; .01 compared to 0.5%" exact="methylcellulose" post="solution-treated controls and oseltamivir-treated groups (log-rank test). The authors"/>
   <result pre="to correspond to human seasonal infection models. In this model," exact="oseltamivir" post="and favipiravir are equally effective and do not differ"/>
   <result pre="to correspond to a novel influenza infection in humans. Although" exact="oseltamivir" post="is ineffective in this model, favipiravir effectively improves survival"/>
   <result pre="macrophage-derived P388D1 cells, and the suppressive effects of favipiravir and" exact="oseltamivir" post="were compared in this P388D1 cell-based system. Favipiravir significantly"/>
   <result pre="influenza virus-infected P388D1 cells compared with the active form of" exact="oseltamivir" post="(Tanaka et al., 2017). TNF-α appears first and disappears"/>
   <result pre="effects of favipiravir treatment on alleviating influenza infection compared with" exact="oseltamivir" post="treatment. Favipiravir displays superior properties to oseltamivir in mouse"/>
   <result pre="infection compared with oseltamivir treatment. Favipiravir displays superior properties to" exact="oseltamivir" post="in mouse models, and we confirmed its efficacy in"/>
   <result pre="to the placebo in alleviating influenza symptoms and to both" exact="oseltamivir" post="and placebo in reducing the viral load 1 day"/>
   <result pre="clearance, and baloxavir-resistant viruses were not cross-resistant to favipiravir and" exact="oseltamivir" post="(Omoto et al., 2018). Baloxavir-resistant viruses were identified after"/>
   <result pre="drugs ineffective during prolonged viral growth in patients treated with" exact="oseltamivir" post="or baloxavir. Although drug-resistant viruses may have a reduced"/>
   <result pre="severe influenza infections characterized by a high viral load than" exact="oseltamivir" post="(Takahashi et al., 2003), and a favipiravir-resistant virus does"/>
   <result pre="exploited in treating patients with severe influenza in combination with" exact="oseltamivir" post="in China (Cao, 2018; Wang et al., 2019). Favipiravir"/>
   <result pre="in China (Cao, 2018; Wang et al., 2019). Favipiravir and" exact="oseltamivir" post="combination therapy accelerated clinical recovery compared to oseltamivir monotherapy"/>
   <result pre="Favipiravir and oseltamivir combination therapy accelerated clinical recovery compared to" exact="oseltamivir" post="monotherapy in severe influenza. The dose of favipiravir used"/>
   <result pre="other existing therapies is also an option and favipiravir and" exact="oseltamivir" post="combination therapy showed accelerated clinical recovery compared to oseltamivir"/>
   <result pre="and oseltamivir combination therapy showed accelerated clinical recovery compared to" exact="oseltamivir" post="monotherapy in severe influenza in China (Cao, 2018; Wang"/>
   <result pre="different from the range of 0.014–0.55 μg/mL in medium without" exact="adenosine" post="and guanosine and 10 μg/mL, respectively (Furuta et al.,"/>
   <result pre="x EC50 (63.7 μM) of adenine, guanine, adenosine, guanosine, and" exact="inosine" post="in the assay medium abolishes the anti-influenza virus activity"/>
   <result pre="strand cannot be completed. In contrast, the anti-RNA virus drug" exact="ribavirin" post="is incorporated into the replicating strand, which further elongates"/>
   <result pre="accumulates mismatched nucleotides at the incorporated sites. Base pairing with" exact="ribavirin" post="in the complementary strand during replication, transcription, and translation"/>
   <result pre="and infectious viruses with mutations in viral RdRp that affect" exact="ribavirin" post="incorporation are produced, drug-resistant viruses can be selected in"/>
   <result pre="to elongate until completion. Next, the RNA strand with multiple" exact="ribavirin" post="incorporation sites further incorporates ribavirin or serves as mRNA"/>
   <result pre="the RNA strand with multiple ribavirin incorporation sites further incorporates" exact="ribavirin" post="or serves as mRNA for viral protein synthesis. The"/>
   <result pre="serves as mRNA for viral protein synthesis. The incorporation of" exact="ribavirin" post="in the viral RNA causes the mismatch of base"/>
   <result pre="(Jin et al., 2013; Sangawa et al., 2013). Favipiravir-RTP and" exact="ribavirin" post="TP inhibit the RdRp activity in a dose-dependent manner,"/>
   <result pre="and a low IC50 (0.14 μM). On the other hand," exact="ribavirin" post="induces competitive inhibition with GTP, and incorporation results in"/>
   <result pre="incorporate labeled GTP without stopping at the incorporation site. Thus," exact="ribavirin" post="has a high IC50 value (2.4 μM) because its"/>
   <result pre="al., 2007; Talarico, Phelps, &amp;amp; Biron, 1993). Penciclovir (famciclovir) and" exact="ganciclovir" post="(valganciclovir), which are guanosine analogues, function as an anti-herpes"/>
   <result pre="activity causes a lower mutation frequency in subjects treated with" exact="penciclovir" post="and ganciclovir than in subjects treated with acyclovir. If"/>
   <result pre="a lower mutation frequency in subjects treated with penciclovir and" exact="ganciclovir" post="than in subjects treated with acyclovir. If favipiravir induces"/>
   <result pre="of favipiravir into viral RNA followed by elongation, similar to" exact="ribavirin" post="or acyclovir (Fig. 5). Favipiravir is unlikely to induce"/>
   <result pre="mutagens such as ribavirin. Ribavirin reduces GTP levels by inhibiting" exact="inosine" post="monophosphate dehydrogenase, but favipiravir has little effect on GTP"/>
   <result pre="assess the emergence of favipiravir-resistant virus, but the appearance of" exact="oseltamivir" post="or baloxavir resistance might be observed in clinical trials"/>
   <result pre="might be observed in clinical trials of influenza treatment with" exact="oseltamivir" post="and baloxavir with a similar number of patients, as"/>
   <result pre="after the start of treatment. Time from illness onset to" exact="oseltamivir" post="treatment in avian influenza A(H7N9) virus infection is 6"/>
   <result pre="respiratory tract of miceActa Virologica53200923324019941386 HawmanD.W.HaddockE.Meade-WhiteK.WilliamsonB.HanleyP.W.RosenkeK. …FeldmannH.Favipiravir (T-705) but not" exact="ribavirin" post="is effective against two distinct strains of Crimean-Congo hemorrhagic"/>
   <result pre="of Dermatological Science232000637210699766 IdaM.KageyamaS.SatoH.KamiyamaT.YamamuraJ.KurokawaM. …ShirakiK.Emergence of resistance to acyclovir and" exact="penciclovir" post="in varicella-zoster virus and genetic analysis of acyclovir-resistant variantsAntiviral"/>
   <result pre="in influenza virus-infected miceChem Pharm Bull (Tokyo)461998144414479775439 KurosakiK.MiwaN.YoshidaY.KurokawaM.KurimotoM.EndoS.ShirakiK.Therapeutic basis of" exact="vidarabine" post="on adenovirus-induced haemorrhagic cystitisAntiviral Chemistry &amp;amp; Chemotherapy15200428128515535050 LaiS.QinY.CowlingB.J.RenX.WardropN.A.GilbertM. …YuH.Global"/>
   <result pre="of Medicine370201452053223614499 LinaB.BoucherC.OsterhausA.MontoA.S.SchuttenM.WhitleyR.J.Nguyen-Van-TamJ.S.Five years of monitoring for the emergence of" exact="oseltamivir" post="resistance in patients with influenza A infections in the"/>
   <result pre="hemorrhagic feverPLoS Neglected Tropical Diseases52011e1342 MiwaN.KurosakiK.YoshidaY.KurokawaM.SaitoS.ShirakiK.Comparative efficacy of acyclovir and" exact="vidarabine" post="on the replication of varicella-zoster virusAntiviral Research652005495515652971 MoriH.ShirakiK.KatoT.HayakawaY.YamanishiK.TakahashiM.Molecular analysis"/>
   <result pre="Research1052014172124583123 OestereichL.RiegerT.LudtkeA.RuibalP.WurrS.PallaschE. …GuntherS.Efficacy of Favipiravir alone and in combination with" exact="ribavirin" post="in a lethal, Immunocompetent mouse model of Lassa feverThe"/>
   <result pre="(H1N1) infectionFrontiers in Immunology102019216131572376 RaabeV.N.KannG.RibnerB.S.MoralesA.VarkeyJ.B.MehtaA.K. …Emory Serious Communicable DiseasesU.Favipiravir and" exact="ribavirin" post="treatment of epidemiologically linked cases of Lassa feverClinical Infectious"/>
   <result pre="fever virus infection and reduces delayed-onset neurologic disease observed with" exact="ribavirin" post="treatmentAntiviral Research1042014849224486952 ShimadaY.SuzukiM.ShirasakiF.SaitoE.SogoK.HasegawaM. …ShirakiK.Genital herpes due to acyclovir-sensitive herpes"/>
   <result pre="TakahashiK.FurutaY.FukudaY.KunoM.KamiyamaT.KozakiK. …ShirakiK.In vitro and in vivo activities of T-705 and" exact="oseltamivir" post="against influenza virusAntiviral Chemistry &amp;amp; Chemotherapy14200323524114694986 TakashitaE.EjimaM.OgawaR.FujisakiS.NeumannG.FurutaY. …OdagiriT.Antiviral susceptibility"/>
   <result pre="(IL)-12 level in the airway of mice administered orally with" exact="clarithromycin" post="or intranasally with IL-12 results in alleviation of influenza"/>
   <result pre="Jan 1434635531309975 VanderlindenE.VranckenB.Van HoudtJ.RajwanshiV.K.GillemotS.AndreiG. …NaesensL.Distinct effects of T-705 (Favipiravir) and" exact="ribavirin" post="on influenza virus replication and viral RNA synthesisAntimicrobial Agents"/>
   <result pre="implicationsVirus Research107200517318115649563 WangY.FanG.SalamA.HorbyP.HaydenF.G.ChenC. …NetworkC. A.-C.Comparative effectiveness of combined favipiravir and" exact="oseltamivir" post="therapy versus oseltamivir monotherapy in critically ill patients with"/>
   <result pre="…NetworkC. A.-C.Comparative effectiveness of combined favipiravir and oseltamivir therapy versus" exact="oseltamivir" post="monotherapy in critically ill patients with influenza virus infectionJ"/>
   <result pre="patients with influenza virus infectionJ Infect Dis2019jiz65610.1093/infdis/jiz65631822885 WestoverJ.B.SefingE.J.BaileyK.W.Van WettereA.J.JungK.H.DagleyA. …GowenB.B.Low-dose" exact="ribavirin" post="potentiates the antiviral activity of favipiravir against hemorrhagic fever"/>
   <result pre="deoxyribonucleoside triphosphate accumulation in Escherichia coliDNA Repair (Amst)420051450145616207537 WhitleyR.J.HaydenF.G.ReisingerK.S.YoungN.DutkowskiR.IpeD. …WardP.Oral" exact="oseltamivir" post="treatment of influenza in childrenThe Pediatric Infectious Disease Journal20200112713311224828"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7106143\results\search\drugs\results.xml">
   <result pre="better guide the antibiotic treatment. PCT is a precursor of" exact="calcitonin" post="that is constitutively secreted by C cells of the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7106487\results\search\drugs\results.xml">
   <result pre="interacts with Ser62, mimicking the carboxy moiety of SAM. The" exact="carbamide" post="spacer allows the two domains to be spaced appropriately"/>
   <result pre="due to its similarity with ZIKV protein. The SAM mimetic" exact="sinefungin" post="was included as control. The MTases were incubated with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7106608\results\search\drugs\results.xml">
   <result pre="PCR &amp;lt; 200 copies/mL) enrolled in a clinical trial of HIV clinic-based" exact="buprenorphine" post="versus referral for methadone among people with opioid use"/>
   <result pre="a clinical trial of HIV clinic-based buprenorphine versus referral for" exact="methadone" post="among people with opioid use disorder in Vietnam. We"/>
   <result pre="with viral suppression (aOR = 25.9, 95% CI = (12.5, 53.8). In bivariate analyses," exact="methamphetamine" post="was negatively correlated with ART prescription (p = 0.07) and viral"/>
   <result pre="began to shift from this model, building clinics to provide" exact="methadone" post="maintenance therapy (MMT) to people with opioid use disorder"/>
   <result pre="with HIV and moderate-to-severe opiate use disorder to receive either" exact="methadone" post="maintenance therapy (MMT) or buprenorphine/naloxone (BUP/NX) at six Vietnamese"/>
   <result pre="Participants were ineligible if they had a known hypersensitivity to" exact="buprenorphine" post="or naloxone, an aspartate aminotransferase or alanine aminotransferase greater"/>
   <result pre="rehabilitation (yes/no), substance use (positive urine drug screen (UDS) for" exact="methamphetamine" post="or amphetamine, methadone, or buprenorphine), and self-reported daily tobacco"/>
   <result pre=" No 230 (81.3%) 160 (83.8%) 159 (84.1%) Positive UDS for" exact="methadone" post="– – – –  Yes 4 (1.4%)  No 279"/>
   <result pre="–  Yes 4 (1.4%)  No 279 (98.6%) Positive UDS for" exact="buprenorphine" post="– – – –  Yes 1 (0.4%)  No 282"/>
   <result pre="eclipsed the potential effect of other participants characteristics, such as" exact="methamphetamine" post="use, supporting the WHO recommendation for offering ART to"/>
   <result pre="the United States have demonstrated the negative association between co-occurring" exact="methamphetamine" post="use and viral suppression [41–44]. Our finding in bivariate"/>
   <result pre="P, Shrestha R, Huedo-Medina TB, Copenhaver M. The impact of" exact="methadone" post="maintenance treatment on HIV risk behaviors among high-risk injection"/>
   <result pre="and HIV viral load suppression in RussiaAIDS Behav20162081603160810.1007/s10461-016-1297-x26809193 41.FeldmanMBet al.Crystal" exact="methamphetamine" post="use and HIV medical outcomes among HIV-infected men who"/>
   <result pre="Alcohol Depend201920217818410.1016/j.drugalcdep.2019.05.00731352308 43.HoodJEet al.The changing burden of HIV attributable to" exact="methamphetamine" post="among men who have sex with men in King"/>
   <result pre="men in King County, WashingtonAIDS Patient Care STDs201832622323310.1089/apc.2017.030629851502 44.FairbairnNet al.Crystal" exact="methamphetamine" post="injection predicts slower HIV RNA suppression among injection drug"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7109339\results\search\drugs\results.xml">
   <result pre="HIV human immunodeficiency virus LDV ledipasvir LMIC low�?middle�?income country SOF" exact="sofosbuvir" post="SSA sub�?Saharan Africa SVR sustained virologic response An estimated"/>
   <result pre="3AfdhalN, ZeuzemS, KwoP, ChojkierM, GitlinN, PuotiM, et al. Ledipasvir and" exact="sofosbuvir" post="for untreated HCV genotype 1 infection. N Engl J"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7109593\results\search\drugs\results.xml">
   <result pre="Utah demonstrated a prompt clinical response after empirical treatment with" exact="doxycycline" post="and delayed development of rickettsia antibodies (5 mo after"/>
   <result pre="signs, graft dysfunction, and eschar and responded well to intravenous" exact="azithromycin" post="and became afebrile within 24 h[53]. Since many cases"/>
   <result pre="study which included 255 solid organ transplant recipients, confirmed that" exact="ribavirin" post="is highly efficient for treating chronic HEV infection and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7112568\results\search\drugs\results.xml">
   <result pre="treatment of one A(H7N9) patient who did not respond to" exact="oseltamivir" post="treatment.16 Convalescent plasma or post-vaccination plasma were also used"/>
   <result pre="were lower in 4 moderately ill patients not treated with" exact="oseltamivir" post="compared with 53 patients who received oseltamivir treatment, including"/>
   <result pre="not treated with oseltamivir compared with 53 patients who received" exact="oseltamivir" post="treatment, including 28 who were severely ill (Supplementary Fig."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7117767\results\search\drugs\results.xml">
   <result pre="μL of viral suspension. The blood meal was supplemented with" exact="adenosine" post="5’-triphosphate (ATP) as a phagostimulant at a final concentration"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7122823\results\search\drugs\results.xml">
   <result pre="in both shaved hind legs (musculus gastrocnemius) under anaesthesia (100 mg/kg" exact="ketamine" post="and 15 mg/kg xylazine). The indicated amounts of DNA plasmids"/>
   <result pre="antigen. At the indicated time points, mice were anaesthetized with" exact="isoflurane" post="and 200 μg D-Luciferin was injected in a volume"/>
   <result pre="mM l-Glutamine, 10 mM HEPES, 50 μM 2-mercaptoethanol and 1% penicillin/streptomycin) containing" exact="monensin" post="(2 μM), anti-CD28 (1 μg/ml, eBioscience), anti-CD107a-FITC (clone eBio1D4B, eBioscience) and"/>
   <result pre="is indicated in the respective experimental part). Under anaesthesia (100 mg/kg" exact="ketamine" post="and 15 mg/kg xylazine), mice got an intranasal instillation of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7128925\results\search\drugs\results.xml">
   <result pre="Northern Ostrobothnia Hospital District, Finland. References References 1Malhotra-KumarS.LammensC.CoenenS.Van HerckK.GoossensH.Effect of" exact="azithromycin" post="and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci"/>
   <result pre="Hospital District, Finland. References References 1Malhotra-KumarS.LammensC.CoenenS.Van HerckK.GoossensH.Effect of azithromycin and" exact="clarithromycin" post="therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7138017\results\search\drugs\results.xml">
   <result pre="National Health Commission suggests taking an anti-HIV drug combination of" exact="lopinavir" post="and ritonavir and inhaling a dose of nebulised interferon"/>
   <result pre="Commission suggests taking an anti-HIV drug combination of lopinavir and" exact="ritonavir" post="and inhaling a dose of nebulised interferon α for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7140199\results\search\drugs\results.xml">
   <result pre="viruses detected in poultry. H7N9 AIVs resistant to adamantine and" exact="oseltamivir" post="cause severe human infection by rapidly inducing progressive acute"/>
   <result pre="NA protein are linked with resistance to NA inhibitors, including" exact="oseltamivir" post="and peramivir.90,94–97 Ribavirin is a well-characterized, broad-spectrum nucleoside inhibitor,"/>
   <result pre="risk of human H7N9 infections would be to administer aerosolized" exact="ribavirin" post="to the nasal mucosa. Regarding drug resistance of HPAI"/>
   <result pre="with amino acid substitutions; R292K confers the highest increase in" exact="oseltamivir" post="half-maximal inhibitory concentration (IC50), E119D confers the highest IC50"/>
   <result pre="in H7N9 treatment is advisable, such as intranasal administration of" exact="ribavirin" post="and baloxavir marboxil, as these have demonstrated effectiveness with"/>
   <result pre="H7N9 virus infection in vitro with three antiviral drugs, oseltamivir," exact="peramivir" post="and favipiravir.Antivir Chem Chemother2014; 23: 237–240. 2013/08/21. DOI: 10.3851/IMP2672.23948557"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7140399\results\search\drugs\results.xml">
   <result pre="testing of antimicrobial compounds, including antibiotics, and identified duramycin and" exact="ivermectin" post="as promising drugs [119]. Furthermore, brain organoids allow for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7140696\results\search\drugs\results.xml">
   <result pre="induction of natural killer (NK) cell development and function (13)" exact="nitric oxide" post="formation [15] and triggering of phagocytic activity of splenic"/>
   <result pre="polymorphisms (rs2549782 and rs2248374) strongly associate with hypersensitivity syndrome to" exact="nevirapine" post="in subjects carrying the HLA-C*04:01 allele. Notably, this report"/>
   <result pre="ARTS-1, Is Required for Interleukin-6 Receptor SheddingJ. Biol. Chem.2003278286772868510.1074/jbc.M30045620012748171 15.GotoY.OgawaK.NakamuraT.J.HattoriA.TsujimotoM.Substrate-Dependent" exact="nitric oxide" post="synthesis by secreted endoplasmic reticulum aminopeptidase 1 in macrophagesJ."/>
   <result pre="and Presented by HLA–B27Arthritis Rheumatol.20146628429410.1002/art.3824924504800 114.CarrD.F.BourgeoisS.ChapondaM.TakeshitaL.Y.MorrisA.P.CastroE.M.C.AlfirevicA.JonesA.R.RigdenD.J.HaldenbyS.et al.Genome-Wide association study of" exact="nevirapine" post="hypersensitivity in a sub-Saharan African HIV-Infected populationJ. Antimicrob. Chemother.2017721152116210.1093/jac/dkw54528062682"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7141683\results\search\drugs\results.xml">
   <result pre="sterile phosphate-buffered saline (PBS). Next, the cells were overlaid with" exact="phenol" post="red free-DMEM medium containing TPCK-treated trypsin (2 μg/mL), 0.6%"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7141694\results\search\drugs\results.xml">
   <result pre="malignancies or chronic illnesses requiring use of steroids (&amp;gt;20mg/day of" exact="prednisolone" post="for &amp;gt; 2 weeks, or other immunosuppressant). Non-probability consecutive"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7144238\results\search\drugs\results.xml">
   <result pre="at Institut Pasteur of Shanghai. Mice were anesthetized with 80 mg/Kg" exact="pentobarbital" post="sodium dissolved in phosphate-buffered saline (PBS) by intraperitoneal injection."/>
   <result pre="GCCCTTTGCGTTATATTGTAT. Histology After mice were anesthetized and sacrificed with 80 mg/Kg" exact="pentobarbital" post="sodium, the chest and abdomen were rapidly opened. The"/>
   <result pre="applying autophagy inhibitors, LY294002 (Figure 6(A)), 3-MA (Figure 6(B)) and" exact="chloroquine" post="(CQ) (Figure 6(C)). As previously reported, our results also"/>
   <result pre="an increasing dose of LY294002 (A) or 3-MA (B) or" exact="chloroquine" post="(C) or Rapamycin (D) for 30 min and then mock-infected"/>
   <result pre="by the US Food and Drug Administration (FDA); oseltamivir, zanamivir," exact="amantadine" post="and rimantadine, these drugs mainly target two of the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7144666\results\search\drugs\results.xml">
   <result pre="of nitrite (NO21−) which is an antimicrobial agent produced from" exact="nitric oxide" post="released by endothelial NO-synthases in saliva [40]. The selected"/>
   <result pre="on NF-CDs and the other with F-CDs For Fe3+:5 ml of" exact="ascorbic acid" post="was added to 1 ml OF human blood sample mixed"/>
   <result pre="of a one step strip test for the detection of" exact="sulfadimidine" post="residuesAnalyst1231219982437244110.1039/a804695f10435274 63MahatoK.ChandraP.Paper-based miniaturized immunosensor for naked eye ALP detection"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7147160\results\search\drugs\results.xml">
   <result pre="pneumonia as a complication during hospitalization. 91.3% SHLCI cases received" exact="oseltamivir" post="treatment, 78.3% before 48 h after admission and 29.5%"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7148454\results\search\drugs\results.xml">
   <result pre="been demonstrated in immunocompetent mouse models in the presence of" exact="cyclosporine" post="A or anti-CD4/anti-SD8 antibodies as immunosuppressant agents [144]. This"/>
   <result pre="from phase Ib reported the combination therapy of CAV21 with" exact="ipilimumab" post="in patients with advanced melanoma [151]. A cohort of"/>
   <result pre="3, 5, 8 and 22, followed by six injections of" exact="ipilimumab" post="(3 mg/kg), beginning on day 22. The ORR was"/>
   <result pre="for metastatic uveal melanomaCancer Immunol. Immunother.2019681179118510.1007/s00262-019-02352-631175402 9.HodiF.S.O’DayS.J.McDermottD.F.WeberR.W.SosmanJ.A.HaanenJ.B.GonzalezR.RobertC.SchadendorfD.HasselJ.C.et al.Improved survival with" exact="ipilimumab" post="in patients with metastatic melanomaN. Engl. J. Med.201036371172310.1056/NEJMoa100346620525992 10.HauschildA.GrobJ.-J.DemidovL.V.JouaryT.GutzmerR.MillwardM.RutkowskiP.BlankC.U.MillerW.H.KaempgenE.et"/>
   <result pre="phase 3 randomised controlled trialLancet201238035836510.1016/S0140-6736(12)60868-X22735384 11.McArthurG.A.ChapmanP.B.RobertC.LarkinJ.HaanenJ.B.DummerR.RibasA.HoggD.HamidO.AsciertoP.A.et al.Safety and efficacy of" exact="vemurafenib" post="in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): Extended follow-up"/>
   <result pre="studyLancet Oncol.20141532333210.1016/S1470-2045(14)70012-924508103 12.RobertC.KaraszewskaB.SchachterJ.RutkowskiP.MackiewiczA.StroiakovskiD.LichinitserM.DummerR.GrangeF.MortierL.et al.Improved overall survival in melanoma with combined" exact="dabrafenib" post="and trametinibN. Engl. J. Med.2015372303910.1056/NEJMoa141269025399551 13.LongG.V.StroyakovskiyD.GogasH.LevchenkoE.De BraudF.LarkinJ.GarbeC.JouaryT.HauschildA.GrobJ.-J.et al.Dabrafenib and"/>
   <result pre="dabrafenib and trametinibN. Engl. J. Med.2015372303910.1056/NEJMoa141269025399551 13.LongG.V.StroyakovskiyD.GogasH.LevchenkoE.De BraudF.LarkinJ.GarbeC.JouaryT.HauschildA.GrobJ.-J.et al.Dabrafenib and" exact="trametinib" post="versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A"/>
   <result pre="trametinibN. Engl. J. Med.2015372303910.1056/NEJMoa141269025399551 13.LongG.V.StroyakovskiyD.GogasH.LevchenkoE.De BraudF.LarkinJ.GarbeC.JouaryT.HauschildA.GrobJ.-J.et al.Dabrafenib and trametinib versus" exact="dabrafenib" post="and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind,"/>
   <result pre="nude miceCurr. Gene Ther.201212677610.2174/15665231280009959922384806 39.JhaB.K.DongB.NguyenC.T.PolyakovaI.SilvermanR.H.Suppression of antiviral innate immunity by" exact="sunitinib" post="enhances oncolytic virotherapyMol. Ther.2013211749175710.1038/mt.2013.11223732991 40.ShapiraS.ShapiraA.KazanovD.HevroniG.KrausS.ArberN.Selective eradication of cancer cells"/>
   <result pre="Treat.2009113213010.1007/s10549-008-9899-218256929 98.SkeldingK.A.BarryR.D.ShafrenD.R.Enhanced oncolysis mediated by Coxsackievirus A21 in combination with" exact="doxorubicin" post="hydrochlorideInvestig. New Drugs20123056858110.1007/s10637-010-9614-021170760 99.BerryL.J.AuG.G.BarryR.D.ShafrenD.R.Potent oncolytic activity of human enteroviruses"/>
   <result pre="clinical trialAnn. Surg Oncol.2016234169417710.1245/s10434-016-5286-027342831 118.PuzanovI.MilhemM.M.MinorD.HamidO.LiA.ChenL.ChastainM.GorskiK.S.AndersonA.ChouJ.et al.Talimogene laherparepvec in combination with" exact="ipilimumab" post="in previously untreated, unresectable stage IIIB-IV melanomaJ. Clin. Oncol.201610.1200/JCO.2016.67.1529"/>
   <result pre="a novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic" exact="ipilimumab" post="in advanced melanoma patients previously treated with anti-PD1 blockade"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7148660\results\search\drugs\results.xml">
   <result pre="to developing severe RSV disease receive passive antiviral immunization with" exact="palivizumab" post="in accordance to French guidelines [8]. Finally, our hospital"/>
   <result pre="of their ALRIs according to the 1999 marketing authorization of" exact="palivizumab" post="by the European Medicines Agency (EMA) [11], the 2007"/>
   <result pre="French Health Authority (HAS), [8] and the 2014 guidance for" exact="palivizumab" post="use of the American Academy of Pediatrics (AAP) [12]."/>
   <result pre="22 (9.2) 21 (9.2) 1 (9.1) Antiviral prophylaxis (n, %)" exact="palivizumab" post="6 (2.5) 6 (2.6) 0 (0.0) 1.0 i.v. or"/>
   <result pre="respectively (p &amp;lt; 0.0001). Among children with community-acquired RSV infections," exact="palivizumab" post="–based prophylaxis was given to 6/18 (33.3%), 6/6 (100%)"/>
   <result pre="versus 0.11%, p &amp;lt; 0.0001). No children with nosocomial RSVreceived" exact="palivizumab" post="–based prophylaxis prior to the onset of their infection."/>
   <result pre="of all RSV-infected inpatients revealed that no other patient required" exact="palivizumab" post="according to the 2007 French and the 2014 American"/>
   <result pre="of new and more cost-effective strategies against RSV infections than" exact="palivizumab" post="(including long acting monoclonal antibodies and vaccines), further larger"/>
   <result pre="Diseasescollab: American Academy of Pediatrics Bronchiolitis Guidelines CommitteeUpdated guidance for" exact="palivizumab" post="prophylaxis among infants and young children at increased risk"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7149541\results\search\drugs\results.xml">
   <result pre="Study Group. Pediatrics 1997;99(1):93–9. https://doi.org/10.1542/peds.99.1.93; . 8989345; . 42MejiasA.RamiloO.Review of" exact="palivizumab" post="in the prophylaxis of respiratory syncytial virus (RSV) in"/>
   <result pre="on the clinical evidence in SpainBMC Infect Dis171201768729041909PMCPMC564598229041909 45ReschB.SommerC.NuijtenM.J.SeidingerS.WalterE.SchoellbauerV.Cost-effectiveness of" exact="palivizumab" post="for respiratory syncytial virus infection in high-risk children, based"/>
   <result pre="AustriaPediatr Infect Dis J3112012e1e82196018721960187 46RajahB.SanchezP.J.Garcia-MaurinoC.LeberA.RamiloO.MejiasA.Impact of the updated guidance for" exact="palivizumab" post="prophylaxis against respiratory syncytial virus infection: a single center"/>
   <result pre="syncytial virus infection: a single center experienceJ Pediatr1812017183188e110.1016/j.jpeds.2016.10.0742785599627855996 47AndersonE.J.Carosone-LinkP.YogevR.YiJ.SimoesE.A.F.Effectiveness of" exact="palivizumab" post="in high-risk infants and children: a propensity score weighted"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7149942\results\search\drugs\results.xml">
   <result pre="specific mutations in the flu strains, and the current favorite" exact="oseltamivir" post="drugs, marketed as Tamiflu, are also reported to be"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7149978\results\search\drugs\results.xml">
   <result pre="inside the liver capsule, hepatotoxic effects of drugs such as" exact="acetaminophen" post="or traditional herbal remedies, and tissue tropism of particular"/>
   <result pre="are 310 petechiae/mm3 (Gubler, 2014). In case of antipyretics, only" exact="paracetamol" post="is recommended to reduce the height of fever, both"/>
   <result pre="indicated if there are no associated bacterial infections. To prevent" exact="paracetamol" post="overdose and hepatotoxicity, a tepid sponge should be used"/>
   <result pre="trials in patients with acute dengue have been conducted with" exact="chloroquine" post="(Tricou et al., 2010) and balapiravir (Nguyen et al.,"/>
   <result pre="the surface of cells via interactions with heparan sulfate and" exact="chondroitin sulfate" post="EPLoS Pathog.3112007e18310.1371/journal.ppat.003018318052531 Ballenger-BrowningK.K.ElderJ.P.Multi-modal Aedes aegypti mosquito reduction interventions and"/>
   <result pre="Flaviviridae genomesJ. Gen. Virol.85Pt 520041113112410.1099/vir.0.19462-015105528 TricouV.MinhN.N.VanT.P.LeeS.J.FarrarJ.WillsB.A randomized controlled trial of" exact="chloroquine" post="for the treatment of dengue in Vietnamese adultsPLoS Negl."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7150763\results\search\drugs\results.xml">
   <result pre="Infect. Dis.2018681665167410.1093/cid/ciy76130202872 39.AbaasaA.AsikiG.Obuku EkiiA.WanyenzeJ.PalaP.van DamG.J.CorstjensP.L.A.M.HughesP.DingS.PantaleoG.et al.Effect of high-intensity versus low-intensity" exact="praziquantel" post="treatment on HIV disease progression in HIV and Schistosoma"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7150882\results\search\drugs\results.xml">
   <result pre="37 °C in LB medium supplemented with 100 μg/mL of" exact="ampicillin" post="until the OD600 reached 0.8. The cultures were inducted"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7150983\results\search\drugs\results.xml">
   <result pre="Sci. USA20061034005401010.1073/pnas.050812310316537476 137.Ming LimC.StephensonR.SalazarA.M.FerrisR.L.TLR3 agonists improve the immunostimulatory potential of" exact="cetuximab" post="against EGFR(+) head and neck cancer cellsOncoimmunology20132e2467710.4161/onci.2467723894722 138.RodaJ.M.PariharR.CarsonW.E.3rdCpG-containing oligodeoxynucleotides"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7151808\results\search\drugs\results.xml">
   <result pre="infectious or autoimmune arthritides. Disease symptoms are usually treated with" exact="paracetamol" post="or non-steroidal anti-inflammatory drugs. Keywords Ross River virus Ross"/>
   <result pre="clothes are also protective. RRV disease is generally treated with" exact="paracetamol" post="or non-steroidal anti-inflammatory drugs (NSAIDs), with many patients being"/>
   <result pre="against SFTSV.18 However, clinical benefit has not been demonstrated by" exact="ribavirin" post="alone, perhaps due to sub-optimal doses and/or late timing"/>
   <result pre="thrombocytopenia syndrome encephalopathyEmerg Infect Dis22720161306130827315224 15LiuWLuQBCuiNCase-fatality ratio and effectiveness of" exact="ribavirin" post="therapy among hospitalized patients in China who had severe"/>
   <result pre="emerging tick-borne zoonosisLancet Infect Dis148201476377224837566 18LeeMJKimKHYiJIn vitro antiviral activity of" exact="ribavirin" post="against severe fever with thrombocytopenia virusKorean J Intern Med32201773173327899013"/>
   <result pre="thrombocytopenia virusKorean J Intern Med32201773173327899013 19LiuWLuQBCuiNCase-fatality ratio and effectiveness of" exact="ribavirin" post="therapy among hospitalized patients with severe fever with thrombocytopneia"/>
   <result pre="treatment cases of severe fever and thrombocytopenia syndrome with oral" exact="ribavirin" post="and plasma exchangeInfect Chemother4912017727728271646 22RyuBHKimJYKimTExtensive severe fever with thrombocytopenia"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7151825\results\search\drugs\results.xml">
   <result pre="of immunosuppression used in autoimmune conditions such as steroids and" exact="methotrexate" post="will also be discussed. •Discuss the implications of different"/>
   <result pre="blockers available. Human monoclonal antibodies, such as adalimumab, certolizumab, and" exact="golimumab" post="work by binding to TNF-alpha and preventing it from"/>
   <result pre="(PML) [6]. 3.6 Nonbiological drugs 3.6.1 Glucocorticoids Glucocorticoids such as" exact="prednisolone" post="or prednisone have been used for decades for their"/>
   <result pre="3.6 Nonbiological drugs 3.6.1 Glucocorticoids Glucocorticoids such as prednisolone or" exact="prednisone" post="have been used for decades for their anti-inflammatory properties."/>
   <result pre="understood. It is generally thought to be safe to continue" exact="methotrexate" post="during a mild, uncomplicated infection but it should be"/>
   <result pre="discussion with the patient's treating specialist. It is unclear whether" exact="methotrexate" post="is associated with an increased risk of particular infections"/>
   <result pre="•Patients taking short or low-dose steroid therapy (&amp;lt;20 mg/day of" exact="prednisolone" post="or equivalent) or inhaled or topical steroids •Patients taking"/>
   <result pre="prednisolone or equivalent) or inhaled or topical steroids •Patients taking" exact="methotrexate" post="at doses of ≤0.4 mg/kg/week or azathioprine at doses"/>
   <result pre="steroids •Patients taking methotrexate at doses of ≤0.4 mg/kg/week or" exact="azathioprine" post="at doses of ≤3 mg/kg/day •Travelers with autoimmune disease"/>
   <result pre="with the following [13] •High-dose corticosteroids—≥20 mg per day of" exact="prednisone" post="or equivalent when administered for ≥2 weeks •Alkylating agents"/>
   <result pre="agents (such as cyclophosphamide). •Antimetabolites (such as higher doses of" exact="methotrexate" post="or azathioprine). •Tumor necrosis factor (TNF) blockers. •Other biologic"/>
   <result pre="blockers. •Other biologic agents that are immunosuppressive or immunomodulatory, e.g.," exact="rituximab" post="or JAK inhibitors 4.3 General implications of significant immunosuppression"/>
   <result pre="of agent. For travel to South and South East Asia" exact="azithromycin" post="is a better choice due to the increased prevalence"/>
   <result pre="campylobacter strains. For patients on biological agents or JAK inhibitors" exact="azithromycin" post="would be a sensible choice of agent as it"/>
   <result pre="with other forms of immunosuppression, including a patient treated with" exact="rituximab" post="[73]. Chronic infection in immunosuppressed patients may rapidly progress"/>
   <result pre="treatment consists of reducing immunosuppression where possible and administration of" exact="ribavirin" post="[75]. A vaccine has been developed against HEV but"/>
   <result pre="case series showed that patients with inflammatory arthritis treated with" exact="infliximab" post="are at greater risk of developing symptomatic coccidioidomycosis than"/>
   <result pre="risk of developing symptomatic coccidioidomycosis than those not treated with" exact="infliximab" post="[94]. Most infections in immunocompetent hosts are either asymptomatic"/>
   <result pre="of diagnosis may be started on oral antifungal treatment, e.g.," exact="fluconazole" post="[92]. Immunosuppressed patients are at greater risk of severe"/>
   <result pre="J Med3588200881181718287603 73FraticelliP.BagnarelliP.TarantinoG.MartinoG.P.BenfaremoD.NobiliL.Chronic hepatitis E in a patient treated with" exact="rituximab" post="and mycophenolate mofetil for Sjogren's syndromeRheumatology551220162275227727498353 74HaagsmaE.B.van den BergA.P.PorteR.J.BenneC.A.VennemaH.ReimerinkJ.H.Chronic"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7152027\results\search\drugs\results.xml">
   <result pre="750 mg three times daily for 7 to 10 days or" exact="tinidazole" post="2 g daily for 3 days should be started empirically"/>
   <result pre="prevent relapse: diloxanide furoate (500 mg orally three times daily) or" exact="paromomycin" post="(30 mg/kg orally in three divided doses). Enteric Fever When"/>
   <result pre="of penicillin (benzylpenicillin 1.5 million units four times daily) or" exact="doxycycline" post="(100 mg twice daily) should be considered in patients with"/>
   <result pre="ticks in southern African game parks should prompt treatment with" exact="doxycycline" post="100 mg twice daily while other infections are excluded. A"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7152106\results\search\drugs\results.xml">
   <result pre="with probenecid. Oral or aerosolized formulations of the broad-spectrum anti-viral" exact="ribavirin" post="inhibit replication of several respiratory viruses, including influenza virus"/>
   <result pre="human and avian viruses are resistant. Neuraminidase inhibitors such as" exact="oseltamivir" post="and zanamivir, which inhibit influenza virus neuraminidase, are effective"/>
   <result pre="should not be withheld in these cases. Parenteral formulations of" exact="oseltamivir" post="and zanamivir and two new neuraminidase inhibitors (peramivir and"/>
   <result pre="be withheld in these cases. Parenteral formulations of oseltamivir and" exact="zanamivir" post="and two new neuraminidase inhibitors (peramivir and laninamivir) are"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7152818\results\search\drugs\results.xml">
   <result pre="were diagnosed with ARDS, 80·8% (42/52) patients were treated with" exact="oseltamivir" post="only, 7·7% (4/52) were treated with combined oseltamivir and"/>
   <result pre="treated with oseltamivir only, 7·7% (4/52) were treated with combined" exact="oseltamivir" post="and peramivir, and 64% (32/50) received glucocorticoids during hospitalization."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7152899\results\search\drugs\results.xml">
   <result pre="of therapy with interferon and no additional benefit from concomitant" exact="tenofovir" post="therapy.19 The international societies, including the American Association for"/>
   <result pre="180 μg weekly; Peg-IFN-α-2b (PegIntron) 1.5 μg/kg weekly. NA treatment:" exact="entecavir" post="(Baraclude) 0.5 to 1 mg daily; tenofovir dipovoxil fumarate"/>
   <result pre="weekly. NA treatment: entecavir (Baraclude) 0.5 to 1 mg daily;" exact="tenofovir" post="dipovoxil fumarate (Viread) 300 mg daily; tenofovir alafenamide (Vemlidy)"/>
   <result pre="1 mg daily; tenofovir dipovoxil fumarate (Viread) 300 mg daily;" exact="tenofovir" post="alafenamide (Vemlidy) 25 mg daily. Abbreviations: ALT, alanine transaminase;"/>
   <result pre="liver tissue is needed for diagnosis. Preemptive antiviral therapy with" exact="valganciclovir" post="has been recommended for SOT recipients at risk, particularly"/>
   <result pre="is negative) who receive allografts from CMV IgG-positive donors.68 Oral" exact="valganciclovir" post="or intravenous ganciclovir may be used to treat CMV"/>
   <result pre="receive allografts from CMV IgG-positive donors.68 Oral valganciclovir or intravenous" exact="ganciclovir" post="may be used to treat CMV hepatitis depending on"/>
   <result pre="alone for hepatitis deltaN Engl J Med3644201132233121268724 19WedemeyerH.YurdaydinC.HardtkeS.Peginterferon alfa-2a plus" exact="tenofovir" post="disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7153335\results\search\drugs\results.xml">
   <result pre="varying heavy tailsConference on Learning Theory2012121 OkellL.C.DrakeleC.J.BousemaT.WhittyC.J.GhaniA.C.Modelling the impact of" exact="artemisinin" post="combination therapy and long-acting treatments on malaria transmission intensityPLoS"/>
   <result pre="new connections: insights from primate-parasite networksTrends Parasitol.337201754756028279627 SaralambaS.Pan-NgumW.MaudeR.J.LeeS.J.TarningJ.LindegårdhN.ChotivanichK.NostenF.DayN.P.SocheatD.WhiteN.J.DondorpA.M.WhiteL.J.Intrahost modeling of" exact="artemisinin" post="resistance in Plasmodium falciparumProc. Natl. Acad. Sci. U. S."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7153856\results\search\drugs\results.xml">
   <result pre="Non-Steroidal Anti-Inflammatory Drugs (NSAID) consists of the following medications ibuprofen," exact="diclofenac" post="and celecoxib. For one participant the data was missing"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7157200\results\search\drugs\results.xml">
   <result pre="32.BaccalaR.KonoD.H.TheofilopoulosA.N.Interferons as pathogenic effectors in autoimmunityImmunol. Rev.200520492610.1111/j.0105-2896.2005.00252.x15790347 33.Cembrzyńska-NowakM.LiebhartJ.Bieńkowska-HabaM.LiebhartE.KulczakA.SiemieniecI.DobekR.DorA.BargW.PanaszekB.The overproduction of" exact="nitric oxide" post="associated with neutrophilic predominance is relevant to airway mycotic"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7157636\results\search\drugs\results.xml">
   <result pre="L-glutamine (Gibco), 100 IU/mL of penicillin (Gibco), 100 μg/mL of" exact="streptomycin" post="(Sigma-Aldrich, Milano, Italy), and 0.25 μg/mL of amphotericin B"/>
   <result pre="cassettes were used. After recombineering, only those colonies that were" exact="kanamycin" post="resistant and chloramphenicol positive were isolated and grown overnight"/>
   <result pre="After recombineering, only those colonies that were kanamycin resistant and" exact="chloramphenicol" post="positive were isolated and grown overnight in 5 mL"/>
   <result pre="of 50 µL, containing 10 mM Tris–hydrochloride pH 8.3, 5%" exact="dimethyl sulfoxide" post="(DMSO), 0.2 mM deoxynucleotide triphosphates, 2.5 mM MgSO4, 50"/>
   <result pre="euthanized at the end of the study (42 dpv) by" exact="pentobarbital" post="overdose. Broncho-alveolar lavage (BAL) was collected from the left"/>
   <result pre="seeded at 7.5 × 105/well in a 6-well dish in" exact="phenol" post="red-free DMEM (Sigma-Aldrich) supplemented with 10% HI FBS (Life"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7157695\results\search\drugs\results.xml">
   <result pre="NOD MiceDiabetes1993421574157810.2337/diab.42.11.15748405697 87.Di GaetanoN.CitteraE.NotaR.VecchiA.GriecoV.ScanzianiE.BottoM.IntronaM.GolayJ.Complement activation determines the therapeutic activity of" exact="rituximab" post="in vivoJ. Immunol.20031711581158710.4049/jimmunol.171.3.158112874252 88.TeijaroJ.R.WalshK.B.CahalanS.FremgenD.M.RobertsE.ScottF.MartinboroughE.PeachR.OldstoneM.B.RosenH.Endothelial cells are central orchestrators of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7157703\results\search\drugs\results.xml">
   <result pre="cell depletion. Importantly, the virus was not found to escape" exact="doxycycline" post="control over time and revert toward a wild type"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7160973\results\search\drugs\results.xml">
   <result pre="the global tobacco epidemic 20172017 2.MerciéPArsandauxJKatlamaCFerretSBeuscartASpadoneCDuvivierCReynesJWirthNMoinotLet al.Efficacy and safety of" exact="varenicline" post="for smoking cessation in people living with HIV in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7168639\results\search\drugs\results.xml">
   <result pre="and additional roles for PER1 and REV-ERBα, as well as" exact="melatonin" post="have been highlighted, as described in the following. The"/>
   <result pre="expression of interferon was also observed as a result of" exact="melatonin" post="administration in a mouse model of VEE (Venezuelan equine"/>
   <result pre="associated with improved response against viruses. This study showed that" exact="melatonin" post="administration results in decreased mortality upon VEE infection [63]."/>
   <result pre="with RSV-related respiratory sepsis [64]. In addition, the administration of" exact="melatonin" post="in the treatment of individuals who are infected with"/>
   <result pre="changes caused by the virus to the host, and thus" exact="melatonin" post="seems to be an interesting nontoxic candidate for future"/>
   <result pre="with venezuelan equine encephalomyelitis virusCell Mol. Life Sci.19975343043410.1007/s0001800500519176561 64.GittoE.KarbownikM.ReiterR.J.TanD.X.CuzzocreaS.ChiurazziP.CordaroS.CoronaG.TrimarchiG.BarberiI.Effects of" exact="melatonin" post="treatment in septic newbornsPediatr. Res.20015075676010.1203/00006450-200112000-0002111726736 65.TanD.X.KorkmazA.ReiterR.J.ManchesterL.C.Ebola virus disease: Potential"/>
   <result pre="in septic newbornsPediatr. Res.20015075676010.1203/00006450-200112000-0002111726736 65.TanD.X.KorkmazA.ReiterR.J.ManchesterL.C.Ebola virus disease: Potential use of" exact="melatonin" post="as a treatmentJ. Pineal. Res.20145738138410.1111/jpi.1218625262626 66.KawaguchiY.TanakaM.YokoymamaA.MatsudaG.KatoK.KagawaH.HiraiK.RoizmanB.Herpes simplex virus 1"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="3-part\PMC7169409\results\search\drugs\results.xml">
   <result pre="results [29,46,47]. The efficacy, route of administration, and dosing of" exact="ribavirin" post="for treatments of respiratory infections have been topics of"/>
   <result pre="treatment of human metapneumovirus pneumonia using combination therapy with intravenous" exact="ribavirin" post="and immune globulinBr. J. Haematol.200914566766910.1111/j.1365-2141.2009.07654.x19344395 47.ParkS.Y.BaekS.LeeS.O.ChoiS.H.KimY.S.WooJ.H.SungH.KimM.N.KimD.Y.LeeJ.H.et al.Efficacy of oral"/>
   <result pre="ribavirin and immune globulinBr. J. Haematol.200914566766910.1111/j.1365-2141.2009.07654.x19344395 47.ParkS.Y.BaekS.LeeS.O.ChoiS.H.KimY.S.WooJ.H.SungH.KimM.N.KimD.Y.LeeJ.H.et al.Efficacy of oral" exact="ribavirin" post="in hematologic disease patients with paramyxovirus infection: Analytic strategy"/>
  </snippets>
 </snippetsTree>
</projectSnippetsTree>
